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ABSTRACT
Kim, Yeon Hee. Effects of Creatine Monohydrate Supplementation on Cytochrome c
and Caspase-9 in Skeletal Muscles from Doxorubicin Treated Rats.
Unpublished Master of Science Thesis. University of Northern Colorado, 2019.

Doxorubicin (DOX) is an effective chemotherapeutic drug for many types of
cancer. However, the deleterious effect of DOX is also observed in heart and skeletal
muscles. Doxorubicin-induced reactive oxygen species (ROS) in mitochondria causes
muscle dysfunction and atrophy leading to the release of cytochrome c (cyt c) and
activation of caspase-9 (casp-9) which cause apoptosis, a programmed cell death in
skeletal muscles. Previous studies have proposed that creatine (Cr) possesses antioxidant
capacity by reducing ROS in oxidative environment. Creatine supplements have shown to
reduce mitochondrial ROS production and decrease apoptotic enzyme activities in
oxidative skeletal muscles; however, Cr’s effects on DOX-induced apoptosis are not yet
fully understood. PURPOSE: To investigate the effects of two different Cr
supplementation protocols on cyt c and casp-9 expression in skeletal muscles from rats
treated with DOX at two different time points. METHODS: Male Sprague Dawley rats
(n=120) were randomly assigned to one of the three different diet treatments: control
(CON, n=40), 2% Cr for four-week (2% Cr, n=40), and the Cr loading consisting of 4%
Cr for one-week followed by three-week of 2% Cr (4% Cr, n=40). Then, each group was
randomly assigned to two different time points for the drug administration: one-day prior
to the sacrifice (1, n=20) and three-day prior to the sacrifice (3, n=20). Lastly, each group
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was randomly assigned to two different drug treatments: 3 mL of saline (SAL, n=10) and
15 mg/kg of DOX (DOX, n=10). The left soleus (SOL) and left extensor digitorum
longus (EDL) were collected after anesthesia and homogenized. A western blot assay was
used to determine protein expression of cyt c and casp-9. RESULTS: No significant
effects of Cr supplementation and DOX administration on cyt c and casp-9 expressions
were observed in both the SOL and EDL (p>0.05). The interaction between the Cr
supplementation and the DOX injection was also not significant (p>0.05). A trend
toward a decrease in cyt c and casp-9 expression was observed in the 4% Cr group of 3SOL and 1-EDL with the DOX injection, but there were no significant differences
(p>0.05). CONCLUSIONS: Even though there were no significant main effects of Cr
diet treatment, DOX administration and no interactions, a potential trend indicated that
the Cr loading protocol may prevent apoptosis by attenuating the expressions of cyt c and
casp-9 in skeletal muscles. Further research with measuring oxidative stress level, protein
synthesis and degradation, and amount of Cr supplementation consumed needs to be
conducted in order to fully understand the mechanism of the Cr supplement and the DOX
administrations in skeletal muscles.
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CHAPTER I
INTRODUCTION
Chemotherapy is one of the major cancer treatments, along with surgery, radiation
therapy, and immunotherapy. The effect of chemotherapy was originated from World
War I when mustard gas was used and found to possess the “anti-carcinogenic” effect.
(Berenblum, 1929). Since then, scientists investigated the effect of chemotherapy for
cancer treatment, and it was introduced to clinics in the early 20th century (Papac, 2001).
Chemotherapy utilizes one or more chemotherapeutic agents to prolong life, reduce
symptoms of cancer, and potentially cure certain types of cancer. Ideally,
chemotherapeutic agents should specifically target neoplastic cells, also called tumors,
and decrease the size of tumors by poisoning the inside of the cell, leading to an
inhibition of mitosis, or cell division. Anti-cancer drug-induced cytotoxicity also has
been observed in normal cells due to a lack of specificity and increased the side effects of
chemotherapeutic drugs including hair loss, anemia, fatigue, and weight loss (Johnstone,
Ruefli, & Lowe, 2002; Coates et al., 1983).
Doxorubicin (DOX) is one of many chemotherapeutic drugs and frequently used
to treat many types of cancers, including leukemia, lymphomas, solid tumors, and
sarcomas (Lipshult et al., 1991). The mechanism of DOX is that the production of
reactive oxygen species (ROS) through its metabolism damages cell membranes,
proteins, and deoxyribonucleic acid (DNA) resulting in cell death (Minotti, Menna,
Salvatorelli, Cairo, & Gianni, 2004). DOX treatment for cancer has been shown to be
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effective; however, DOX-induced toxicity also has been observed to cause critical
damage in normal tissues including heart and skeletal muscles (Hydock, Lien, Jensen,
Schneider, & Hayward, 2011). In skeletal muscle, DOX treatment decreased force
production and the level of contractile proteins and initiated cell death because of DOXinduced ROS production (Min et al., 2015). Therefore, the usage of DOX treatment has
been limited in the clinics due to its toxicity in healthy tissues.
Reactive oxygen species (ROS) are molecules that contain oxygen and are
produced by the metabolism of oxygen (Devasagayam et al., 2004). Reactive oxygen
species are often taken up by the antioxidant defense enzyme such as superoxide
dismutase (SOD) to prevent ROS from reacting with other molecules. (Valko et al.,
2007). The accumulation of ROS, known as oxidative stress, damages macromolecules
such as carbohydrates, lipids, protein, and DNA and may initiate apoptosis (Birben,
Sahiner, Sackesen, Erzurum, & Kalayci, 2012). It is essential to tightly regulate oxidative
stress because it can cause many pathological conditions including neurodegenerative
disease, gene mutations, inflammatory disease, chronic fatigue syndrome, and cancer
(Sies, Stahl, & Sundquist, 1992).
Apoptosis is a tightly regulated programmed cell death, and it is a normal event as
a homeostatic mechanism in tissues (Alberts et al., 2008). Apoptosis is often triggered by
physical or pathological conditions such as DNA damage and the overproduction of ROS
(Norbury, & Hickson, 2001; Yuan, Murrell, Trickett, & Wang, 2003). This programmed
cell death is often initiated by the release of apoptosis-inducing factors (AIF) such as
cytochrome c and the activation of proapoptotic proteins including caspase-9 and
caspase-3. Preventing the initiation of apoptosis is critical especially when there is too
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much apoptosis because it can cause neurodegenerative diseases, ischemic damage, and
atrophy in tissues (Elmore, 2007).
Creatine (Cr) is an organic compound that is produced primarily in the liver and
consumed through a regular diet (Walker, 1979). The ergogenic effect of Cr as a
supplement is well known to enhance exercise performance such as power, strength, and
speed with exercise training (M. Bemben, D. Bemben, Loftiss, & Knehans, 2001; Skare,
Skadberg, & Wisnes, 2001). Recently, researchers have proposed a direct antioxidant
capacity of Cr. Creatine as a supplement has shown to scavenge free radicals, specifically
superoxide anion (•O−2) and peroxynitrite (OONO−) and reduce the level of free radicals
induced by exercise in skeletal muscle (Deminice & Jordao, 2012; Guimarães-Ferreira et
al., 2012; Lawler, Barnes, Wu, Song, & Demaree, 2002). This direct antioxidant capacity
of Cr has been debatable due to unclear exact mechanisms; however, the creatine
supplement seemed to activate an intracellular signaling pathway that regulates
mitochondrial function in oxidative skeletal muscle and reduce apoptotic enzyme
activities by activating the anti-apoptotic pathway in ischemic heart tissue (Ceddia &
Sweeney, 2004; Caretti et al., 2010).
Therefore, doxorubicin treatment is well-known to be effective in many types of
cancers; however, the mechanism of DOX induces toxicity in heart and skeletal muscles
by producing an excessive amount of ROS. Doxorubicin-induced damage in skeletal
muscles can lead to decrease force production and contractile proteins, causing apoptosis.
The direct antioxidant effect of Cr supplement can be potentially one of preventive
interventions for ROS-induced apoptosis in skeletal muscles treated with DOX.
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Statement of Purpose
The main purpose of this study was to investigate the effects of in vivo DOX
administration at two different time points prior to rat sacrifice (one- and three-day) on
the expressions of the apoptotic initiator proteins cytochrome c and caspase-9 in type I
and type II skeletal muscle fibers. The second purpose of this study was to explore the
effects of two different Cr supplementations, 2% Cr supplementation for four-week and
Cr loading treatment consisting of 4% Cr supplementation for one-week then followed by
2% Cr supplementation for three-week, on cytochrome c and caspase-9 expressions in
type I and type II skeletal muscle fibers. The third purpose of this study was to examine
the interaction between the Cr supplementation and the DOX administration in type I and
type II skeletal muscle fibers.
Research Hypotheses
H1

DOX administration at 1-day and 3-day prior to rat sacrifice will increase
cytochrome c and caspase-9 expressions in both the soleus (SOL) and
extensor digitorum longus (EDL).

H2

Both Cr supplementation treatments, 2% Cr and 4% Cr, will attenuate the
increased cytochrome c and caspase-9 protein expressions in both the SOL
and EDL.

H3

Both Cr supplementations treatment, 2% Cr and 4% Cr, will attenuate the
effects of DOX on cytochrome c and caspase-9 expressions in both the
SOL and EDL.

H4

The Cr loading treatment, one week of 4% Cr supplementation followed
by three weeks of 2% Cr supplementation, will provide the greatest degree
of protection against the effects of DOX on cytochrome c and caspase-9
expressions in both the SOL and EDL.
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CHAPTER II
REVIEW OF LITERATURE
Doxorubicin (DOX)
Doxorubicin (DOX) is an anthracycline chemotherapeutic agent used to treat
leukemia, lymphomas, and solid tumors such as breast, lung, gastric, and soft tissue
sarcomas (Lipshult et al., 1991). Doxorubicin is composed of daunosamine and an
addition of hydroxyl group at carbon 14 position (Takemura & Fujiwara, 2007). The
main metabolic pathway for DOX is going under redox cycling where the reduction of
two electrons yields doxorubicinol, a secondary alcohol, or one electron reduction with
oxidoreductases including cytosolic nicotinamide adenine dinucleotide phosphate
hydrogen, (NAD(P)H), xanthine oxidase, and synthases lead to form a doxorubicinsemiquinone radical. Due to its structure, the doxorubicin-semiquinone is an unstable
metabolite so that it converts back to doxorubicin immediately. During this process, it
releases reactive oxygen species (ROS), which can lead to lipid peroxidation, the
oxidative degradation of fatty acids. Reactive oxygen species-induced lipid peroxidation
can lead to membrane damage, DNA damage, oxidative stress, and eventually, it can
continue to apoptotic pathways of cell death (Doroshow, 1986). The DOX chemotherapy
has been effective in fighting against cancer by inducing DNA damage with the
inhibition of topoisomerase II, an enzyme which manages DNA tangles and supercoils
and by increasing oxidative stress which will lead to ROS-induced apoptosis (Gewirtz,
1999; Minotti et al., 2004; Momparler, Karon, Siegel, & Avila, 1976; Wang et al., 2004).
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While the DOX chemotherapy is highly effective in DNA damaging for cancer cells, it
also can damage healthy cells, especially in heart tissue with an increase in DOX-induced
ROS causing cardiotoxicity (L'Ecuyer et al., 2006; Yoshida, Shiojima, Ikeda, & Komuro,
2009). Therefore, DOX treatment has been limited to decrease the damage in normal
healthy tissues.
Reactive Oxygen Species (ROS)
Reactive oxygen species are atoms or a group of atoms that have one or more
unpaired electrons such as superoxide (•O−2), hydrogen peroxide (H2O2), hydroxyl radical
(·OH), and hydroperoxyl (HO2). They are endogenously generated in the process of
mitochondrial oxidative phosphorylation, or the interaction of exogenous factors can lead
to the accumulation of ROS. When there is an imbalance between the production of ROS
and the cellular antioxidant defenses, oxidative stress occurs and causes ROS-mediated
damage in nucleic acids, proteins, and lipids which can directly or indirectly result in
cancer, diabetes, neurodegeneration, and atherosclerosis (Ray, Huang, & Tsuji, 2012).
Reactive oxygen species are often produced by oxidoreductases such as
NAD(P)H, and xanthine oxidase in cell membranes, mitochondria, and endoplasmic
reticulum. Mitochondrial ROS are generated in the process of oxidative phosphorylation
where mitochondria convert energy into a form of adenosine triphosphate (ATP) as a
product of citric acid cycle, fatty acid oxidation, and amino acid oxidation (Muller,
2000). The process of ATP synthesis in mitochondria involves the transport of hydrogen
ions (H+) across the inner mitochondrial membrane utilizing an enzymatic series of
electron donors and acceptors, called the electron transport chain (ETC). The first
electron acceptor, called complex I, accepts electrons from NADH, which is an electron
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carrier from the citric acid cycle. The electrons get passed down to coenzyme Q, which
also accepts electrons from complex II. Coenzyme Q continues to pass down electrons to
complex III, then to cytochrome c. The final complex is complex IV, where oxygen is
reduced to water (H2O) (Han, Williams, & Cadenas, 200; Muller, 2000). In the process of
passing electrons to oxygen, a small number of electrons do not complete the whole
series which results in converting oxygen into the free radical, superoxide (•O−2) by
NADPH and xanthine oxidase (Muller, Lustgarten, Jang, Richardson, & Van Remmen,
2007). Superoxide is mostly generated during complex I and III and initiates lipid
peroxidation when it converts to hydrogen peroxide (H2O2) (Li et al., 2013). Due to the
toxicity of •O−2 at high concentration, the antioxidant defense enzyme, superoxide
dismutase (SOD), efficiently catalyzes superoxide into H2O2 (Valko et al., 2007). H2O2
can be converted to hydroperoxyl (·OH) which is highly reactive and can lead to damage
of macromolecules, including nucleic acids, carbohydrate, lipids, and amino acids. To
prevent the accumulation of ·OH, H2O2 can also be quickly decomposed by the
peroxisomal enzyme, called catalase, into oxygen and water (Birben et al., 2012; Reiter et
al., 1995).
Apoptosis
Apoptosis is defined as a form of programmed cell death which is a highly
regulated and controlled process in multicellular organisms unlike necrosis, a form of
traumatic cell death from acute cell injuries (Alberts et al., 2008). Apoptosis is a normal
event during development and aging as a homeostatic mechanism in tissues. This
programmed cell death can act as an immunity defense system when cells are damaged
by disease, or physiological and pathological conditions can trigger apoptotic cell death.
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Apoptosis can be induced by direct exposure of cells to ROS, including H2O2 and ·OH
(Buttke & Sandstrom, 1994; Norbury & Hickson, 2001). Also, chemotherapeutic drugs
result in DNA damage and can lead to a p53-dependent apoptotic pathway in cancer
cells. Either too little or too much of apoptosis is critical in many human conditions,
including neurodegenerative diseases, ischemic damage, autoimmune disorders, atrophy,
and many types of cancers (Elmore, 2007).
Apoptosis can be activated by one of two main apoptotic pathways: the
extrinsic/death receptor pathway and the intrinsic/mitochondrial pathway. The extrinsic
pathway involves death receptors that are members of the tumor necrosis factor (TNF)
receptor gene superfamily (Locksley, Killeen, & Lenardo, 2001). The TNF receptor
family contains a cytoplasmic “death domain” that transmits the death signal to the
intracellular signaling pathways from the cell surface. Once extracellular ligands
including FasL and TNF-α bind to the TNF receptors with the death domain, a deathinducing signaling complex (DISC) is formed, leading to the activation of caspases,
essential protease enzymes in apoptosis. The cleaved caspases (activation form of
caspase) can activate other procaspases (an inactivated form of caspase) and allow to
initiate the caspase cascade leading to apoptosis (Elmore, 2007; Peter & Krammer, 1998).
The intrinsic apoptosis pathway is initiated in response to non-receptor-mediated
stimuli including radiation, hypoxia, increased intracellular concentration of free fatty
acids, and ROS (Cotran & Kumar, 1998; Hardy et al., 2003; Mattson & Chan, 2003).
These stimuli that initiate the intrinsic pathway produce intracellular signals which can
act directly on targets of a cell and are the events initiated by mitochondria. p53-mediated
apoptosis is an example of the intracellular signaling apoptotic pathway. The tumor
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suppressor gene p53 is a transcription factor that regulates the cell cycle. The apoptotic
stimuli such as DNA damage at the G1/S phase of the cell cycle activate p53 and initiate
the apoptosis. The activation of p53 regulates Bcl-2 family of the proteins which play a
role in mitochondrial membrane permeability. The proteins of the Bcl-2 family can be
either pro-apoptotic or anti-apoptotic. For example, Bax and Bak are the pro-apoptotic
proteins of the Bcl-2 family and formed an oligomeric pore in the outer mitochondrial
membrane.
The anti-apoptotic proteins Bcl-2 and Bcl-x physically block the oligomeric pore
of Bax and Bak and prevents the release of cyt c from mitochondria to the cytoplasm.
The activation of p53 by DNA damage recognition leads to a conformational change in
Bax/Bak and Bcl-2/Bcl-x resulting in the release of cytochrome c (cyt c) from inner
mitochondria to the cytoplasm (Cory & Adams, 2002; Elmore, 2007; Schuler & Green,
2001). Then, the mitochondria-mediated apoptosis occurs when the release of cyt c
activates apoptotic protease activating factor-1 (Apaf-1) as well as procaspase-9 (Saelens
et al., 2004). Cleaved caspase-9 is an initiator caspase of caspase cascade and leads to
activating the effector caspases such as caspase-3, -6, and -7 resulting in apoptosis (Rai,
Tripathi, Sharma, & Shukla, 2005). Additionally, Smac/Diablo, the secondary
mitochondria-derived activator of caspases, binds to inhibitor of apoptosis proteins and
enhances caspases activation (Susin et al., 1999).
In addition, calcium (Ca2+) plays an essential role in the initiation of the intrinsic
apoptotic pathway. The homeostasis of Ca2+ is tightly regulated in mitochondria. The
concentration of Ca2+ in mitochondria can be increased by a Ca2+ uniporter, transporting
Ca2+ from the cytosol into mitochondria, or pathological conditions. The Ca2+-mediated
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initiation of apoptosis is associated with an opening of mitochondrial permeability
transition (MPT) pore. The large accumulation of Ca2+ in mitochondria can lead to
osmotic swelling, and then it ends up with bursting the mitochondrial membrane. The
rupture of the membrane can release cyt c into the cytosol through the opening of MPT
(Orrenius, Gogvadze, & Zhivotovsky, 2015).
Additionally, Ca2+ can dephosphorylate the Bcl-2 family, including Bax and Bak
by the protein phosphate calcineurin which is often activated by Ca2+. This
dephosphorylation of Bax and Bak triggers the unblock of Bcl-2 and Bcl-x on Bax/Bak
on the outer mitochondrial membrane and leads to the release of cyt c to the cytoplasm
(Wang, Lin-Shiau, & Lin, 1999). The Ca2+-mediated activation of calpain in the
mitochondria can initiate apoptosis in the cell as well. The entry of Ca2+ into the inner
mitochondria can directly activate mitochondrial calpain. Then calpain promotes the
cleavage of cardiolipin, which anchors apoptosis-inducing factors (AIF) including cyt c
in the inner mitochondrial membrane. The release of AIF via cleavage of cardiolipin into
the cytosol can cause DNA fragmentation and initiate cell death (Orrenius et al., 2015).
Cytochrome c (Cyt c)
Cytochrome c (cyt c) is a highly water-soluble hemeprotein involved in the ETC
in the mitochondria. The heme group of cyt c accepts and transfers electrons to the
complex IV, the final complex of ETC (Han, Williams, & Cadenas, 2001; Muller, 2000).
Cyt c is also involved in the initiation of apoptosis. It binds to cardiolipin in the inner
mitochondrial membrane, which prevents it from releasing cyt c out of mitochondria and
initiating apoptosis when there is no intracellular apoptotic signal. Without apoptotic
stimuli, cyt c is usually in a reduced form and is not capable of initiating the intrinsic
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apoptotic pathway. When an apoptotic stimulus is present such as ROS produced by
mitochondria, cyt c becomes oxidized by NAD(P)H and causes an opening of the MPT
pore. Then the oxidized cyt c is detached from cardiolipin and released through the MPT
pore into the cytoplasm (Matsuura, Canfield, Feng, & Kurokawa, 2016). Also, the release
of cyt c is highly regulated by the Bcl-2 family via p53 mediated apoptotic pathway. The
p53-mediated conformational change of Bax/Bak makes an opening on mitochondrial
membrane and allow cyt c to pass through the oligomeric pore of Bax/Bak from
mitochondria to the cytoplasm (Meyer, Kim, & Penn, 2006). The release of cyt c triggers
the formation of the apoptosome, which is assembled with a one-to-one ratio of cyt c and
Apaf-1. The sevenfold symmetric structure of apoptosomes leads to an activation of
procaspase-9, an initiator caspase of caspase cascade resulting in apoptosis (Ferraro,
Fuoco, Strappazzon, & Cecconi, (2010).
Karpinich, Tafani, Rothman, Russo, and Farber (2002) showed the importance
of cyt c in maintaining healthy cells has been shown in their study. The L929 mouse
fibroblasts were treated with ten µM of etoposide, which is a topoisomerase II inhibitor
and induces DNA damage. The etoposide-treated fibroblasts showed expression of cyt c
in the cytoplasm by western blot assay after 24 hours. Also, the percentage of dead cells
increased by 48.1 ± 2.4 % after 72 hours of etoposide treatment. This data suggests that
the release of cyt c induced cell death to regulate fibroblasts with DNA damage induced
by etoposide. In addition, oxidative stress by ROS can induce the cyt c release in the
cytoplasm. Human tendon was treated with high concentration (50 µM) of H2O2 for 12
hours, and a significant increase of apoptotic cells (8%) was detected compared to the
control group (p<0.05). Only after 4 hours of 50 µM of H2O2 exposure in tendon cells,
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the release of cyt c was expressed by western blot assay while there was no detectable cyt
c expression in control cultured human tendon cells. The oxidative stress-induced cyt c
release resulted in a threefold increase in caspase-3 activity (Yuan et al., 2003).
Another study suggested that lipid peroxidation induces cyt c release from
mitochondria by breaking the bond of cyt c and cardiolipin. The bovine heart was treated
with oxygen gas overnight leading to an increase in the formation of a conjugated diene,
the marker for lipid peroxidation. The lipid peroxidation led to a less effective activity
between cardiolipin and cyt c resulting in release of cyt c to the cytoplasm from
mitochondria (Shidoji, Hayashi, Komura, Ohishi, & Yagi, 1999). Additionally, it has
been shown that the increase in the release of cyt c from mitochondria was induced by
Ca2+-mediated mitochondrial swelling in the brain and liver tissue of rats. The induction
of MPT was observed using a spectrophotometer, and the rapid reduction of light
absorbance indicated a rise in mitochondrial swelling. The mitochondria from both brain
and liver tissues, treated with 100 µM Ca2+, caused a large decrease in light absorbance.
This Ca2+-induced mitochondrial swelling led to an increase in the release of cyt c from
mitochondria, detected by western blot assay (Kobayashi et al., 2003). These studies
suggested that the release of cyt c can be caused by DNA damage, ROS-induced
oxidative stress, lipid peroxidation, or Ca2+-induced mitochondrial swelling leading to
cell death.
Caspase-9 (Casp-9)
Caspase-9 (casp-9) is a family of cysteine-aspartic protease (caspase) involved in
apoptosis and found in the mitochondria, cytosol, and nucleus. Casp-9 is an initiator
caspase of the caspase cascade and plays a critical role for the apoptotic pathway in many
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tissues. Procaspase-9 is the form expressed in an inactive proenzyme, and cleaved
caspase-9 is the active form of proenzyme caused by apoptotic signals (Kuida, 2000).
Caspase-9 has three domains: N-terminal pro-domain, large subunit, and a small subunit.
The N-terminal pro-domain contains the caspase activation domain (CARD) where it
binds to CARD of Apaf-1 (Li et al., 2017). The release of cyt c and activated Apaf-1 by
apoptotic signals cause dimerization of procaspase-9 resulting in formation of cleaved
casp-9. Once it is activated, the caspase cascade initiates with cleaved casp-9 cleaving
another procaspase-9 for its dimerization or activating the executioner caspases including
caspase-3, -6, and -7, leading to apoptosis (Druskovic, Suput, & Milisav, 2006;
Zhivotovsky, Samali, Gahm, & Orrenius, 1999).
Cleaved casp-9 is an essential enzyme to initiate apoptosis via caspase cascade in
mitochondria. In the HeLa cell with immunodepletion of casp-9, it failed to activate the
executioner caspase, caspase-3. According to Li et al., (1997), the protease cascade
leading to apoptosis was initiated as soon as cleaved casp-9 rapidly activated caspase-3 in
normal healthy HeLa cell. In another experiment, ROS such as H2O2 induced p53dependent apoptosis. The loss of mitochondrial membrane permeability due to an
injection of H2O2 (25 and 50 µM) in HeLa cells resulted in the release of cytochrome c
leading to a significant increase in the cleavage of procaspase-9 compared to the control
without the H2O2 treatment (p<0.01). The 25 µM H2O2-induced activation of procasp-9
significantly increased the activation of the caspase-3-mediated apoptosis (p<0.001)
(Pallepati & Averill-Bates, 2011). In Wang et al. study (1999), flavonoid-induced ROS
activated the procaspase-9 in human promyelocytic leukemia HL-60 cells treated with 60
µM of flavonoid, a strong antioxidant treatment. The time-dependent cleavage of
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procaspase-9 was increased after 12 hours of flavonoid treatment by western blot assay,
and it was consistent with DNA fragmentation and the activity of caspase-3. The study
suggested that flavonoid metabolic process induced the ROS production due to its
structure which led to mitochondrial dysfunction, and resulted in the activation of casp-9
and caspase-3, leading to apoptosis. In a cancer cachexia mouse model, increased
caspase-dependent proteolytic activity was observed due to weight loss with the depletion
of skeletal muscle and adipose tissue. Among mice with weight loss (from 2% to 25%)
after MAC 16 or MAC 13 tumor implantation, the activity of caspase-9 and caspase-3
increased by 177% and 98%, respectively, in gastrocnemius muscles (Belizário, Lorite, &
Tisdale, 2001). This suggested that the weight loss was caused by caspase-dependent
apoptosis in skeletal muscle cells. From these previous studies, cleaved caspase-9 plays a
critical apoptotic initiator enzyme which induces the activation of caspase-3, leading to
apoptosis in cells.
Doxorubicin-Induced Apoptosis
Lipid Peroxidation
Lipid peroxidation is the oxidative degradation of fatty acids, especially
polyunsaturated fatty acids due to their multiple double bonds in between methylene
bridges that possess primarily reactive hydrogen atoms. The lipid peroxidation is initiated
by ROS such as ·OH and H2O2 taking electrons from lipids in the cell membrane
producing the fatty acid radicals. The fatty acid radical is not a stable molecule by losing
an electron, which leads to reacting with oxygen, forming peroxyl-fatty acids. The final
products of lipid oxidation are malondialdehyde (MDA) and 4-hydroxynonenal (HNE),
and they are important biomarkers of oxidative stress (Mylonas & Kouretas, 1999). MDA
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and HNE are considered to be mutagenic and causal agents for many diseases such as
diabetes, chronic inflammation, neurodegenerative disease, osteoarthritis, and different
types of cancer (Tiku, Narla, Jain, & Yalamanchili, 2007; Zarkovic, 2003).
According to Myers et al. (1977), DOX-induced lipid peroxidation results from
increased ROS production by DOX metabolism with NAD(P)H and xanthine oxidase.
Their study showed that MDA was detected in normal mouse cardiac tissues two days
after the injection of DOX (15 mg/kg) in the peritoneum while the control cardiac tissues
without the DOX injection had no MDA detected. After four days of the injection, MDA
reached a peak concentration of 53 ± 10 μM. (Myers et al., 1977). Another study found
that the formation of conjugate diene-containing lipids, resulted from peroxidation of
unsaturated lipids, increased in cultured cardiomyocytes of Wistar rats exposed to 1 μM
DOX. The DOX-treated cardiomyocyte had a significant increase of 1.6 fold in
comparison to the cells not exposed to DOX in the first three hours after drug exposure
(p<0.01). Also, there was a linear correlation between the conjugate diene-lipid level and
the time of exposure in the first three hours (r=0.996) (Hrelia et al., 2002). The increase
in intracellular ceramide, a biomarker of lipid peroxidation, was observed in rat cardiac
myocyte with one hour treatment of DOX (0.5 μM). The DOX-induced lipid peroxidation
led to apoptosis after 7-day of the DOX treatment in cardiomyocyte. Lipid peroxidationinduced apoptosis was prevented in cardiac myocyte with the treatment of L-carnitine
(200 μg/ml), a compound with protective effect on cardiac metabolism (Andrieu-Abaddie
et al., 1999).
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Deoxyribonucleic Acid (DNA)
Damage
Several mechanisms have been proposed for DOX-mediated deoxyribonucleic
acid (DNA) damage, including topoisomerase inhibition, DNA adduct formation, and
oxidative stress by ROS (Yang, Teves, Kemp, & Henikoff, 2014). The DOX-induced
topoisomerase II poisoning has been clinically used to increase double-strand DNA
breaks, resulting in DNA damage and cell death. Topoisomerase II is an ATP-dependent
enzyme that binds DNA supercoils and entangled DNA and releases torsional stress
formed during DNA replication and transcription. Additionally, topoisomerase II is
important for separating two topologically-linked daughter chromosomes during mitosis,
and topoisomerase II inhibition prevents healthy cells from dividing into two daughter
cells resulting in apoptosis (Carpenter & Porter, 2004; Pommier, Leo, Zhang, &
Marchand, 2010). Doxorubicin-induced topoisomerase II inhibition has a similar
mechanism as etoposide which traps a topoisomerase II at breakage sites, stabilizes the
cleavage complex, and impedes DNA resealing (Nitiss, 2009; Wu et al., 2011). In
primary mouse embryonic fibroblasts (MEF) with DNA topoisomerase II β knockout
(top2β−/−), the level of DOX-induced γ-H2AX, a key DNA damage signal induced by
double-strand DNA breaks, reduced in comparison with MEFs with DNA topoisomerase
IIβ (TOP2β+/+). This study suggests that the DOX mediates DNA damage signal γ-H2AX
with topoisomerase IIβ (Lyu et al., 2007).
Additionally, topoisomerase IIβ was mainly involved in DOX-induced heart
failure, which is a side effect of damaging non-dividing cells. It has been shown that
TOP2β+/+ cardiomyocytes of mice, injected with 25 mg/kg DOX and harvested 16 hours
later had an increase of p53-inducible gene (Trp53inp1) that regulates apoptosis by 200-
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fold. The genes involved in the apoptotic pathway, such as Apaf1, Bax, and Fas, showed
an upregulation of their transcriptions. The upregulations of pro-apoptotic genes were
only expressed in DOX-treated TOP2β+/+ mice but not in top2β−/− mice with the same
DOX treatment (Zhang et al., 2012). These findings suggest that DOX treatment can
force cardiomyocytes into apoptosis by double-strand DNA breaks utilizing
topoisomerase IIβ.
Doxorubicin is also able to cause DNA adduct formation as a DNA intercalator
and activate DNA damage responses leading to topoisomerase II-independent cell death
(Chaires, Herrera, & Waring, 1990; Chen, Gresh, & Pullman, 1986; Swift, Rephaeli,
Nudelman, Phillips, & Cutts, 2006). Doxorubicin is more likely to intercalate at the
adjacent GC base pairs due to specific hydrogen bond formation between DOX and
guanine. A covalent bond mediated by formaldehyde, generated by free radical reactions
from lipids and spermine, plays a primary role to stabilize DOX and DNA interaction.
This interaction involves DOX forming a covalent bond with guanine on one strand of
DNA mediated by formaldehyde and hydrogen bonds with guanine on the opposing
strand (Taatjes, Gaudiano, Resing, & Koch, 1996). In cultured breast cancer cells (MCF7), the elevated level of formaldehyde was observed with the highest concentration of
DOX treatment (50 µM). The DOX sensitive MCF-7 cells had a higher formaldehyde
count by 16.7 ± 4.3 compared to the DOX-resistant MCF-7 cells (Kato, Burke, Fenick,
Taatjes, & Bierbaum, 2000). Another DOX-induced DNA adduct experiment was
performed in the promyelocytic leukemia cell line HL-60 and the mitoxantrone resistant
variant HL-60/MX2, which has a decreased expression of topoisomerase IIα and no
detectable levels of topoisomerase IIβ. Doxorubicin concentration-dependent DNA

18
adduct formation in the presence of formaldehyde increased from ~2 adducts per 10 kb
DNA for one µmol/L of DOX to ~8.5 adducts per 10 kb DNA for four µmol/L of DOX.
The cells were also treated with a combination of DOX (1, 2, and 4 µmol/L) and
pivaloyloxymethyl butyrate (AN-9, 50 µmol/L), a compound that releases formaldehyde
upon hydrolysis. The adduct formation with the combination treatment increased DOX
concentration-dependent apoptosis in both HL-60 and HL-60/MX2 cells, 30-50%, and
20-50% respectively. The activity level of Caspase-3/7, the executioners in apoptosis,
was also measured, and the pattern of the activity was matched with the pattern of
induction of apoptosis by sub-G1 DNA content analysis and by DNA fragmentation. They
showed that DOX-induced DNA adducts in the formation of formaldehyde could lead to
a DOX concentration-dependent apoptosis in leukemia cells (Swift et al., 2006).
Although evidence suggests that DNA damage-induced apoptosis in cancer cells
and cardiomyocytes by topoisomerase II and DNA adducts with DOX treatments, they
are unlikely to be the important mechanisms of doxorubicin action. According to Pang et
al. (2013), human melanoma cells were treated with a standard clinical dosage, 9 µM of
DOX with inhibition of topoisomerase II and it strongly induced apoptosis which was led
by histone eviction. Additionally, a clinical dose for DOX (typically >10 µM) causes
only 4.4 ± 1.0 adduts/107 base pair DNA, and it is a small fraction of total DOX
(Coldwell, Cutts, Ognibene, Henderson, & Phillips, 2008).
Further studies were investigated for more mechanisms of DOX-induced DNA
damage besides the inhibition of topoisomerase II and DNA adduction. A different
mechanism was found that DOX can also be oxidized into doxorubicin-semiquinone
radicals through redox cycling by oxidoreductases including NAD(P)H and xanthine
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synthase (Doroshow, Synold, Somlo, Akman, & Gajewski, 2001). Due to the instability
of semiquinone radicals, they immediately react with oxygen and produce ROS including
•

O−2 and H2O2 leading to DNA damage (Berlin & Haseltine, 1981; Minotti et al., 2004).

According to Myers (1998), DOX can bind to metal molecules and form a DOX-iron
complex. This bond catalyzes H2O2 to ·OH which is a highly reactive molecule.
Doxorubicin-induced ROS can lead to oxidative stress and result in DNA damage
and apoptosis (Thorn et al., 2011). In previous studies, researchers suggested that the
redox cycling of DOX by NADH dehydrogenase induced oxidative stress and led to
DNA base modifications. Oxidative DNA bases such as thymine glycol and 8hydroxyguanine are mutagenic and are produced by ·OH characteristic chemical species
in human chromatins (Basu, Loechler, Leadon, & Essigmann, 1989; Shibutani, Takeshita,
& Grollman, 1991). Another study showed that erythrocytes from breast cancer patients
had a significant increase in DNA base oxidation by DOX-induced ROS after 72 to 96
hours of intravenous infusion of 1 µM of DOX (p<0.02) (Doroshow et al., 2001). In
H9C2 rat cardiomyocytes, the oxidized DNA bases, including 8-hydroxyguanine and
pyrimidines, were observed and induced the activity of p53 (L'Ecuyer et al., 2006). The
relationship between oxidative stress and DNA damage were examined in cultured
cardiomyocyte of rats. With the 1 µM of DOX treatment for four and eight hours, DNA
damage increased as oxidative stress increased. Also, the accumulation of p53 and
cleaved caspase-3 expression were detected by western blot assay (p<0.05). The
apoptotic cell death was also observed after eight hours of DOX treatment. DOX-induced
oxidative stress and p53 expression were reduced by a free radical scavenger, N-AcetylCystine, indicating that DOX-induced ROS resulting in p53-dependent apoptosis in
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cardiomyocyte. In the p53 mice model with 6 mg/kg of DOX treatment for four weeks,
an increased in impaired contractile function and apoptotic cardiomyocytes in p53 wild
type mice model were detected compared to p53 heterozygous knockout mice (p<0.05). It
was suggested that p53 accumulation and apoptotic cardiomyocyte were caused by DOXinduced ROS, resulting in DNA damage (Yoshida et al., 2009).
In another study, a significantly elevated level of cytosolic cyt c was observed in
mitochondria of DOX (20 mg/kg) treated cardiomyocytes of rats compared to the control
group (p=0.033). Also, the positive correlation of cytosolic cyt c and caspase-3 activity
was found in the DOX-treated group (r=0.88, p=0.003). These findings suggested that the
in vivo levels of cyt c in the cytoplasm of cardiomyocytes directly affect caspase-3
activity, which results in apoptosis. The significantly elevated level of 8-iso-PGF2α, a
marker of oxidative stress to lipids, was detected in the cytosol of rats treated with DOX
(p=0.036). This result suggests that DOX induces oxidative stress in vivo and leads to an
elevated cyt c release resulting in apoptosis of cardiomyocyte of rats (Childs, Phaneuf,
Dirks, Phillips, & Leeuwenburgh, 2002). These DNA base modifications and oxidative
stress by ROS can promote mutations and impair the functions of replication and
transcription, resulting in cell death (Jena, 2012).
Doxorubicin and Skeletal Muscle
The DOX chemotherapy has been associated with myotoxicity in many tissues,
including cardiac and skeletal muscle. Dorxorubicin-induced skeletal muscle toxicity has
resulted in an increase in muscle dysfunction, fatigue, and atrophy depending on time and
injection dosage (Brehdal, Pfannenstiel, Quinn, Hayward, & Hydock, 2016; Hydock et
al., 2011; Smuder, Kavazis, Min, & Powers, 2011; Van Norren et al., 2009). This
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deleterious effect of DOX is a serious problem because it directly affects activities of
daily living (ADL) requiring the utilization of skeletal muscle in cancer patients
undergoing DOX chemotherapy (Schwartz, 2000).
The contractile dysfunction of extensor digitorum longus (EDL) of the mouse was
observed with DOX treatment (50 – 175 µM) for 0 – 2 hours in ex vivo and in vitro
assays. Due to the significantly longer relaxation time at 90 – 100% of the maximal force
in all of the different dosages of DOX (p<0.05), maximal force, contraction and
relaxation velocity significantly decreased in a time- and dose-dependent manners
(p<0.05). The slower relaxation velocity is associated with impaired relaxation, which is
directly related to the rate of calcium (Ca2+) clearance from the cytoplasm. They further
investigated a calcium influx with oxidative stress, which was applied to C2C12
myotubes and resulted in producing ROS due to a mitochondrial malfunction. Even
though the increase in ROS led to cell death in C2C12 cells, the increase in Ca2+ influx
was not observed (MacLennan, 2000; Van Norren et al., 2009). However, Abramson,
Buck, Salama, Casida, and Pessah (1988) found evidence that DOX (< 10 µM) induced
Ca2+ release by 50-60% in rabbit skeletal muscle sarcoplasmic reticulum (SR), which
stores Ca2+ and regulates contraction and relaxation in skeletal muscle. This study
suggested that DOX-induced Ca2+ release from SR has a direct dose-dependent
interaction with the ryanodine receptor (RYR) complex, a calcium release channel, by
increasing the sensitivity of calcium activator site of RYR.
The increase in intracellular Ca2+ release can trigger the caspase cascade and
calpain, a Ca2+-dependent protease (on caspase protease) involved in apoptosis (Momeni,
2011). A piece of evidence showed that 20 mg/kg of DOX injection in soleus (SOL)
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muscle of rats 24 hours before sacrifice activated protease, including calpain and caspase3. The ratio of calpain-to-calpastatin (calpain inhibitor) was significantly higher
compared to the control group without DOX (p<0.05). Also, the expression of cleaved
caspase-3, often activated by casp-9 in the caspase cascade, was significantly higher than
the control group in a western blot assay (p<0.05). These results showed that the DOX
treatment triggered apoptosis via caspase protease and on caspase protease in SOL
muscle.
Additionally, one of the contractile proteins of skeletal muscle, actin, was
observed as a marker of muscle proteolysis. The increase in activity of calpain and
caspase-3 significantly lowered the actin level in SOL with DOX treatment compared to
the control group without DOX and the endurance exercise training group without DOX
treatment (p<0.05). The percentage of myofilament release showed a significant increase
(p<0.05) in SOL with 20 mg/kg of DOX injection due to the loss of actin leading to
reduction of skeletal muscle cross-sectional which can cause the contractile dysfunction
(Smuder et al., 2011). Another study showed that Ca2+-mediated calpain activation
significantly increased in the diaphragm, plantaris, and soleus of rat model with the
clinical dosage (20 mg/kg) of DOX injection 48 hours prior to sacrifice. The active
calpain can cause the release of cyt c and AIF by breaking the bond of cardiolipin and
inner mitochondrial membrane (Min et al., 2015). Then, the release of cyt c and AIF
triggers DNA fragmentation and initiates apoptosis in cells.
Doxorubicin-induced contractile dysfunction and atrophy can be triggered by a
large amount of DOX-induced ROS production, leading to oxidative stress in skeletal
muscle (Min et al., 2015; Montaigne et al., 2011). In Min et al. study (2015), the
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significant increase in mitochondrial ROS emission was detected in the diaphragm,
plantaris, and soleus muscles with 20 mg/kg of DOX treatment in rats (p<0.05). Besides,
the mitochondrial-targeted antioxidant, SS31, was utilized with DOX treatment in all
three tissues, and the DOX-mediated mitochondrial ROS emission was prevented. They
also observed oxidative damage in muscle proteins triggered by the DOX-mediated
mitochondrial ROS production. The level of 4-HNE, a biomarker of lipid peroxidation,
was significantly increased with the DOX treatment (20 mg/kg) compared to the control
group without the DOX injection (p<0.05). Important to note, the tissues with SS31
treatment prevented the increase in 4-HNE, indicating that the DOX-mediated
mitochondrial ROS emission resulted in oxidative stress in the skeletal muscle, causing
lipid peroxidation. The increase in mitochondrial ROS emission by the DOX treatment in
diaphragm led to a significant reduction in diaphragmatic specific force production
compared to the control group. Additionally, there was a significant decrease in myofiber
cross-section area (CSA) in all three skeletal muscles including the diaphragm, plantaris
and soleus muscles (p<0.05), however, the reduction in myofiber CSA was protected
with the antioxidant treatment of SS31 in these tissues. This indicated that DOX-induced
mitochondrial ROS caused contractile dysfunction and skeletal muscle atrophy.
Interestingly, cardiolipin, the anchorage protein for AIF and inner mitochondria
membrane, can also be readily peroxidized in ROS-induced oxidative environment and
promote the opening of MPT leading to release of AIF including cyt c besides the
mechanism that the Ca2+-mediated calpain activation dephosphorylates cardiolipin
(Montaigne et al., 2011). Therefore, DOX treatment induces mitochondrial ROS
production leading to oxidative damage in skeletal muscle and promotes the opening of
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MPT pores by ROS-mediated cardiolipin dephosphorylation causing the release of AIF
from the mitochondria.
Doxorubicin-induced mitochondrial ROS production can also upregulate the
muscle regulatory proteins, causing muscle degradation in skeletal muscle. For example,
E3 ubiquitin ligases, including atrogin-1/MAFbx and MuRF1, are mainly involved in
muscle protein degradation. The upregulation of these proteins can be found in many
catabolic situations such as inflammation and starvation (Dogra et al., 2007; Jagoe,
Lecker, Gomes, & Goldberg, 2002). Evidence showed that the exposure of 0.2 µM DOX
to C2C12 myotube led to a significantly increased level of atrogin-1/MAFbx mRNA,
along with a rise in protein 24 hours after the exposure (p<0.05). However, DOX
treatment in C2C12 myotubes altered neither of the levels of MuRF1 mRNA or MuRF1
protein level. To ensure the increase in atrogin-1/MAFbx mRNA and protein levels was
affected by the DOX-induced mitochondrial ROS emission, C2C12 was treated with the
mitochondrial-targeted antioxidant, SS31. The level of atrogin-1/MAFbx mRNA was
reduced with the SS31 treatment and the decrease in myotube width and the loss of
contractile proteins including myosin and actin, caused by DOX treatment, were
prevented as well (Gilliam et al., 2012).
These previous studies showed that the DOX treatment induced apoptosis via
activating Ca2+-mediated calpain leading to the increase in the opening of MPT pores in
mitochondria which released AIF including cyt c to the cytoplasm. In addition, DOXinduced mitochondrial ROS production could increase the level of MPT pores by lipid
peroxidation of mitochondrial membrane and the mRNA level of E3 ubiquitin ligases
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involved in muscle protein degradation such as atrogin-1/MAFbx. The DOX-mediated
apoptosis in skeletal muscle leads to contractile dysfunction and muscle atrophy.
Creatine
Creatine (Cr) is an organic compound that is endogenously synthesized with two
amino acids, arginine, and glycine, that are combined by the enzyme arginine:glycine
amidinotransferase (AGAT). The combination of arginine and glycine forms
guanidinoacetate which is methylated with S-adenosyl methionine by guanidinoacetate
N-methyltransferase, leading to the formation of Cr. The synthesis of Cr primarily occurs
in the liver and is transported to other organs that store and utilize Cr through the blood.
By utilizing its concentration gradient, Cr is diffused and transported through sodium and
chloride dependent transporter into tissues from the blood. Most of Cr (95% of total Cr)
becomes stored in skeletal muscle while the remaining 5% of the Cr can be found in the
blood, brain, liver, and kidney. In addition, Cr can also be obtained by dietary intake, and
the average Cr uptake from the diet is ~1g/day in young adults (Walker, 1979).
Creatine kinase (CK) can convert Cr and ATP to phosphocreatine (PCr) and
adenosine diphosphate (ADP). PCr can be seen as an energy buffer in the PCr energy
system because it can form ATP and Cr through the reversible reaction of CK. This
reversible reaction of PCr plays an essential role in rapid ATP production during highintensity, short duration (~10 seconds) exercises such as sprints and repeated bouts of
maximum weight lifting. The formation of ATP and Cr from PCr becomes favored due to
the low pH level caused by the rapid accumulation of lactic acid produced by highintensity anaerobic exercise (Demant & Rhodes, 1999; Walker, 1979; Yquel, Arsac,
Thiaudiere, Canioni, & Manier, 2002). The accumulation of intracellular Cr
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concentration from 19 to 32 mM in rat SOL and extensor digitorum longus (EDL)
muscles increased the maximum Ca2+-activated force by 104 ± 1 and 105 ± 1%,
respectively, by increasing Ca2+ sensitivity in skeletal muscle. This study suggested that
an increase in Cr concentration resulted in increased maximum force in skeletal muscle
(Murphy, Stephenson, & Lamb, 2004).
Creatine monohydrate supplementation is well known to facilitate in increasing
total Cr concentration in muscles. The ingestion of 20g of creatine monohydrate
supplement for five days increased the muscle total Cr concentration and PCr
concentration by 18% and 10%, respectively (Casey, Constantin-Teodosiu, Howell,
Hultman, & Greenhaff, 1996). Another study showed a similar result with the intake of
20 to 30g of creatine monohydrate per day for two days significantly increasing total Cr
concentration by 20 to 40% in the quadriceps femoris muscles of 17 healthy participants.
This increase in total muscle Cr concentration can enhance performance and decrease
fatigue during anaerobic exercise (Harris, Söderlund, & Hultman, 1992). In Hultman,
Söderlund, Timmons, Cederblad, and Greenhaff study (1996), the effects of creatine
loading treatment was also investigated in vastus lateralis muscle of health men. The
group with 20 g/day Cr supplements for six days followed by 2 g/day for the next 28 days
had a rapid increase in total Cr concentration by ~16 mmol/kg dry mass after 6-day of the
20 g/day Cr consumption. The Cr loading group maintained the elevated total Cr
concentration in vastus lateralis muscle after 28-day when the group without the Cr
loading protocol declined its total Cr concentration (p<0.05).
Many researchers have shown that the effect of the creatine monohydrate
supplementation is positively associated with exercise performance. The Cr loading (9g
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per day for six days) significantly increased the volume of the 1-rep max (RM) deadlift
compared to the placebo group without the Cr supplementation (p=0.010) (F. Rossouw,
Kruger, & J. Rossouw, 2000). Nine weeks of Cr supplementation (20g per day for five
days followed by 5g per day for the rest of days) with a strength training program showed
an improvement in exercise performance in collegiate football players (M. Bemben et al.,
2001). The Cr supplement group showed significant increases in body weight and lean
body mass post Cr supplement consumption (p<0.05). Also, anaerobic strength improved
in all three lifts, including bench press, power clean, and squat by 5.2%, 3.8%, and 8.7%,
respectively. In addition, the Wingate bicycle ergometer test was performed to measure
anaerobic power and capacity, and the Cr group improved in both anaerobic power and
anaerobic capacity by 19.6% and 18.4%, respectively (M. Bemben et al., 2001). The
improvement in exercise performance with Cr supplementation also was shown in sprint
performance. The intake of 5g Cr supplement for five days significantly increased body
weight in professional male sprinters compared to pre-Cr supplement consumption
(p<0.05). The participants in the Cr group showed a significant decrease in 100 m sprint
time from 11.68 seconds to 11.59 seconds (p<0.02) (Skare et al., 2001).
Creatine monohydrate supplementation also showed the effect in myofibrillar
protein and myosin heavy chain (MHC) protein with resistance training for six months.
Total body mass and strength significantly increased in the Cr supplementation group
compared to the control group and the placebo group only with the resistance training
(p<0.05). Additionally, the myofibrillar protein expression and the MHC protein
expression increased by 57.92% and 17.49%, respectively, in the Cr supplement group
with the training (Willoughby & Rosene, 2001). The effect of Cr supplementation during
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exercise training enhances the power, strength, and speed by delaying fatigue and
increasing the muscle protein expression.
Although many studies have focused on the improvement of exercise performance
with the Cr supplement, recent investigations have proposed the antioxidant effect of Cr
in the oxidative environment. Lawler et al. (2002) investigated the association between
antioxidant scavenging capacity (SAC) and creatine. In a dose-dependent manner, a
significant relationship between SAC and Cr concentration was found (r=0.88), which
indicated the direct antioxidant capacity of Cr. The antioxidant effect of Cr only affected
on •O−2 and peroxynitrite (OONO−) in this study. The treatment with 40 mM Cr resulted
in a significant increase in quenching •O−2 compared to the control group. The SOD
equivalent units of •O−2 quenching in the control group and Cr group were 4 ± 9 and 68.0
± 32.5, respectively. A similar result was shown in H2O2 quenching with 40 mM Cr;
however, the significant difference was not observed between the control and Cr groups.
The OONO− quenching also significantly increased in a dose-dependent manner, and the
most effective Cr concentration of the removal of OONO− was found to be at 60 mM Cr.
These results indicate that Cr possesses the direct antioxidant capacity in the removal of
•

O−2 and OONO−. The formation of Cr with arginine can explain the ability of Cr to

scavenge free radicals. Arginine has an antioxidant capacity by quenching •O−2, generated
by xanthine oxidase or released from endothelial cells. Since Cr is synthesized with
arginine and glycine, the study suggests that the antioxidant effect of arginine may be
possessed in Cr as well (Lawler et al., 2002).
In Guimarães-Ferreira et al. (2012) study, H2O2 production significantly
decreased in Cr-treated SOL and EDL muscles of rat (p<0.01 and p<0.05, respectively).
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The SOL and EDL were treated with 5 g/kg creatine for six days. The percent change of
H2O2 compared to the control group without Cr treatment in SOL and EDL muscles were
59 % and 76.3%, respectively. Creatine supplementation in SOL and EDL did not affect
the level of antioxidant enzyme mRNA including the primers for SOD, mitochondrial
manganese SOD, and catalase indicating the direct antioxidant capacity of Cr.
Another study performed investigated the antioxidant capacity of Cr with acute
exercise training in rats. The acute exercise training group with a 2% creatine
monohydrate diet for 28 days had a significant increase in total muscle Cr concentration
(p<0.05) compared to the control group that did not receive the Cr diet. Plasma
thiobarbituric acid reactive species (TBARS), a byproduct of lipid peroxidation, and total
lipid hydroperoxide were observed as markers for oxidative stress-induced ROS in
skeletal muscle. In SOL and gastrocnemius muscles with the Cr diet, the level of TBARS
decreased by 20% after six hours and total lipid hydroperoxide level also decreased by
20% after six hours. These results indicated that the 2% Cr monohydrate diet directly
facilitated the antioxidant activity in increased oxidative stress markers caused by acute
exercise (Deminice & Jordao, 2012).
An excessive ROS production in skeletal muscle is one of many mechanisms that
trigger apoptosis via mitochondrial dysfunction in skeletal muscle. According to Ceddia
and Sweeney (2004), 5’ adenosine monophosphate-activated protein kinase (AMPK)
signaling plays a key role in ROS-induced mitochondrial dysfunction/impairment, muscle
atrophy, and sarcopenia, a loss of muscle mass. It has been suggested that Cr supplement
increased in the activity of AMPK via glucose oxidation. The production of 14CO2,
radioactive carbon dioxide, was observed as a marker of glucose oxidation. In L6 rat
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myoblasts treated with 0.5 mM Cr, the basal production of 14CO2 significantly increased
by 1.4-fold compared to the control group without the Cr treatment (p<0.05). AMP
kinase activity was measured, and the significant increase in AMPK activity was
observed with a ~2.2-fold increase (p<0.05). This study suggested that the increased
activation of AMPK activity with Cr treatment might prevent mitochondrial dysfunction.
However, it was unknown if AMPK activity also increased in oxidative damaged skeletal
muscle.
Even though the exact mechanism of Cr supplementation preventing ROSinduced apoptosis is not known, the Cr supplement has shown to prevent apoptosis in
ischemic cells via activating the anti-apoptotic pathway. The H9c2 cardiomyocytes
treated with 0.5 µM of DOX, significantly decreased the cell viability by 35% (p<0.001).
The Cr treatments (2.5 mM Cr, 5 mM Cr, and 10 mM Cr) significantly increased
compared to the only DOX treated cell in a dose-dependent manner (p<0.05). The 50.4%
decreased cell viability was also observed in ischemic cardiomyocytes, restricted with
blood supply, compared to the control group (p<0.001). Unlike the DOX treated cells, the
2.5 mM Cr treatment did not increase the cell viability; however, the combination of 5
mM ribose and 2.5 mM Cr significantly improved cell viability by 30% (p<0.01). The
apoptotic enzymes, cleaved caspase-3 and poly ADP-ribose polymerase (PARP), were
observed in control, Cr and, ribose treated ischemic H9c2 cells. The Cr and ribose
treatment significantly reduced the protein expressions of cleaved caspase-3 and PARP
compared to the untreated ischemic cell (p<0.5). The increased activation of Akt
pathway, known as an anti-apoptotic pathway, was observed in Cr and ribose treated
ischemic cardiomyocytes (p<0.05). The study suggested that the Cr and ribose
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supplementation could activate the anti-apoptotic pathway and prevent apoptosis in DOX
treated and ischemic cardiomyocytes. However, the antioxidant effects of Cr supplement
treatment were not found to prevent DOX-induced apoptosis in cardiomyocytes (Caretti
et al., 2010).
Conclusion
DOX is a highly effective chemotherapeutic drug used in many types of cancer.
Due to its structure, DOX often goes into redox cycling with NAD(P)H and induces the
release of ROS, leading to lipid peroxidation, DNA damage, and oxidative stress in cells
(Doroshow, 1986; Gewirtz, 1999). The usage of DOX in the clinic has been limited
because the excessive release of ROS results in toxicities and triggers apoptosis in many
tissues, including heart and skeletal muscle (Minotti et al., 2004). The contractile
dysfunction, including maximal force, contraction, and relaxation velocity, is induced by
DOX treatment, which increases mitochondrial ROS production. Doxorubicin-induced
apoptosis in skeletal muscle is initiated via the opening of MPT pores which often is
induced by Ca2+-mediated mitochondrial swelling, the excessive release of the
mitochondrial ROS production, and activation of calpain which releases AIF including
cyt c into cytoplasm (Min et al., 2015; Smuder et al., 2011; Van Norren et al., 2009).
The release of cyt c from mitochondria is a biomarker for the initiation of
apoptosis. The mitochondrial ROS production causes DNA damage and lipid
peroxidation, which damages the inner mitochondrial membrane. The damage of the
membrane in mitochondria breaks the bond between cardiolipin and cyt c, leading to the
release of cyt c. Additionally, ROS production induces the proapoptotic Bcl-2 family
proteins including Bax/Bak and release cyt c through the pore formation of Bax/Bak into
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the cytoplasm from mitochondria. The formation of apoptosome with Apaf-1 and cyt c
cleaves procaspase-9 and initiates the apoptotic caspase-cascade, resulting in apoptosis
(Cory & Adams, 2002; Saelens et al., 2004). The regulation of apoptosis is critical in
skeletal muscles because the decreased in muscle contractile proteins results in
contractile dysfunction and muscle atrophy (Gilliam et al., 2012; Min et al., 2015).
Creatine is an organic compound, primarily synthesized in the liver and obtained
by the diet. The ergogenic capacity of Cr via the PCr energy system has shown with the
reversible reaction of CK. The rapid production of ATP from PCr and ADP occurs during
high-intensity, and short duration exercises that lowers the pH and favors the formation
of Cr and ATP. Creatine supplementation increases total muscle Cr concentration in
skeletal muscle and improves exercise performance by delaying fatigue and increasing
contractile muscle proteins with exercise training (Cory & Adams, 2002; Saelens et al.,
2004).
Besides the positive effect of Cr on exercise performance, some researchers
suggest a direct antioxidant capacity of Cr. The ability to quench ROS, •O−2, and
OONO−, has shown (Lawler et al., 2002). Additionally, decreased levels of H2O2,
TBARS, and lipid hydroperoxide has been observed with Cr supplementation and
exercise training in skeletal muscles (Deminice & Jordao, 2012; Guimarães-Ferreira et
al., 2012). Creatine supplementation possibly prevents ROS-induced mitochondrial
dysfunction and apoptosis via activation of the AMPK pathway and reduces apoptotic
enzyme activities by activating the anti-apoptotic Akt pathway (Ceddia & Sweeney,
2004; Caretti et al., 2010).
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In summary, DOX is a highly effective therapeutic drug for many types of
cancers; however, its clinical usage is limited due to producing an excessive amount of
ROS in heart and skeletal muscles during the process of its metabolism. The DOXinduced ROS release in mitochondria leads to lipid peroxidation, DNA damage, and
oxidative stress triggering apoptosis in cells. The apoptosis is initiated by initiator
apoptotic enzymes, cyt c and casp-9. Doxorubicin-induced mitochondrial ROS
production releases cyt c into cytoplasm and activates casp-9 leading to apoptosis.
Doxorubicin-induced apoptosis is critical in skeletal muscles because it results in
contractile dysfunction and muscle atrophy. Recent findings have suggested that Cr
supplement reduces mitochondrial ROS production and potentially prevents initiation of
apoptosis in skeletal muscles with its direct antioxidant effect; however, its exact
mechanism is not yet fully understood.
This study demonstrates the potential intervention for preventing the initiation of
apoptosis caused by DOX-induced ROS production in mitochondria with creatine
supplementation. As previous literatures mentioned, the antioxidant capacity of creatine
should reduce apoptosis, which is initiated by DOX-induced ROS production and
oxidative stress in skeletal muscles.
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CHAPTER III
METHODS
Experimental Design
All the procedures were approved by University of Northern Colorado
Institutional Animal Use and Care Committee and followed the Animal Welfare Act.
Ten-week-old male Sprague Dawley rats (Envigo, Indianapolis, IN, N=120) were
individually housed and maintained on a 12:12 hour light-dark cycle at normal room
temperature and humidity. Rats were provided with rodent chow and water ad libitum.
They were randomly divided into three groups: normal chow (CON, n=40), 2% creatine
chow (2% Cr, n=40), and the creatine loading diet consisting of one week of 4% creatine
chow followed by three weeks of 2% creatine chow (4% Cr, n=40). Each group was then,
again, randomly assigned into two groups which included 1-day injection prior to
sacrifice (1, n=20) and 3-day injection prior to sacrifice (3, n=20). Lastly, each group was
randomly divided into two groups: doxorubicin (DOX, n=10) and saline (SAL, n=10).
The treatments for the groups are shown in figure 1. The 2% Cr groups were provided
with chow that contained 2% creatine (Sigma-Aldrich, St.Louis, MO) for four weeks,
while the 4% Cr groups were provided with 4% creatine chow (Sigma-Aldrich, St.Louis,
MO) for one week followed by 2% creatine chow for the remaining three weeks. Body
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mass (g) for all animals were measured once a week during the four-week nutritional
intervention and prior to sacrifice.
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(n=40)

1-Day
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Figure 1. Experimental Design of Diet Treatments for Groups.
Drug Treatment
DOX-1 and SAL-1 were injected with 15 mg/kg body weight of DOX
hydrochloride (Bedford Labs, Bedford, OH) and 3 mL of SAL, respectively, one day
prior to sacrifice. DOX-3 and SAL-3 were also injected with DOX 15 mg/kg body weight
and 3mL of SAL, respectively, three days prior to sacrifice.
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Biochemical Analysis
Extensor Digitorum Longus and
Soleus Preparation
At the determined point, each animal was injected with sodium pentobarbitol (50
mg/kg) in the lower left abdominal region prior to sacrifice. The tail was pinched to
ensure the absence of a tail-pinch reflex indicating no pain or discomfort. The left
extensor digitorum longus (EDL) and left soleus (SOL) were removed, weighed, and
flash frozen in liquid nitrogen. All tissues were stored in a laboratory freezer at -80°C
until biochemical analysis.
Homogenate Preparation
Frozen portions of the EDL and SOL between 0.07 g and 0.1 g were used for
homogenization. Muscle samples were manually homogenized with
radioimmunoprecipitation assay (RIPA, SigmaAldrich: St. Louis, MO) buffer (1:10 tissue
mass:volume) and 10 µL of protease enzyme inhibitor (SigmaAldrich: St. Louis, MO) in
a glass tissue homogenizer. Cell membranes were further disrupted with a sonicator
(Sonic disembrator model 100, Fisher Scientific, Hampton, NH) with ten, one second
pulses. Samples were then transferred to centrifuge tubes and centrifuged for ten minutes
at 10,000g. The supernatant was collected, and total protein concentration analyzed using
the Bradford (Bradford, 1976). Protein concentration was standardized with RIPA buffer,
and an equal volume of Lammeli buffer was added to each sample.
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Western Blotting
Electrophoresis was conducted to separate proteins by molecular weight (kDa)
using an Xcell II blot module (Invitrogen, LifeTechnologies) on 4-20% gradient TrisGlycine precast gels (LifeTechnologies, Carlsbad, CA). Before loading onto gels,
samples were heated in boiling water for two minutes and transferred to an ice bucket for
ten minutes. Gels were placed and locked in the Xcell II blot module and the middle
section was filled with running buffer (100 mL Tris-Glycine Running Buffer (10X): 900
mL deionized (DI) water). Each 15 µL of sample was loaded on to gels, and 10 µL of
SeeBlue®Plus2 protein ladder (Novex, LifeTechnologies) and 10 µL of MagicMark™
XP standard ladder (Novex, Lifetechnologies) were also loaded on the gels as standards.
The outside of the chamber was also filled with Tris-glycine running buffer. Gels were
run at 125 V and 0.04 A until proteins migrated to the bottom of gels.
Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Novex,
LifeTechnologies) with two filter papers soaked in transfer buffer (40 mL Tris-Glycine
transfer buffer, 200 mL methanol, and 760 mL DI water). The soaked membranes, filter
papers, and pads were stacked in the following order: 1) two soaked pads on the bottom
2) one filter paper 3) gel-1 4) membrane 5) one filter paper 6) one soaked pad 7) filter
paper 8) gel-2 9) membrane 10) filter paper 11) two soaked pads. The soaked membranes
were rolled with glass pipette to remove air bubbles between the gels and the transfer
buffer was poured into the middle of chamber, and DI water filled the outside of the
chamber. The protein transfer was run for 90 minutes at 25 mV and 0.10 A. Once
proteins were transferred onto the membranes, the membranes were washed with 20 mL
of DI water for five minutes, four times, and then blocked with 10 mL of SuperBlock
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blocking buffer (Thermoscientific, Rockford, IL) for thirty minutes using a laboratory
rocker. PVDF membranes were rinsed again with 20 mL of DI water for five minutes,
four times.
The membranes were incubated for 15 – 18 hours with 10 mL of mouse
monoclonal primary antibodies for cytochrome c (1:200, Santa Cruz Biotechnology:
Dallas, TX) or cleaved caspase-9 (1:200, Santa Cruz Biotechnology: Dallas, TX). The
mouse monoclonal antibody GAPDH (1:500, Santa Cruz: Dallas, TX) was used as the
loading control. PVDF membranes were washed with 20 mL of TBST for five minutes
and repeated four times and rinsed with 20 mL of DI water for five minutes, twice.
Membranes were incubated in 10 mL of anti-mouse secondary antibody (1:1000, Santa
Cruz: Dallas, TX) for one hour. Membranes were again washed with 20 mL of TBST for
five minutes, four times and then were rinsed with 20 mL of DI water for five minutes,
twice.
Protein imaging was completed using enhanced chemoluminescence (ECL) (CDigit, Li-Cor, Lincoln, NE), and protein expression was quantified by ImageJ software
(NIH, Bethesda, MD). 750 mL of luminol and enhancer (C-Digit, Li-Cor: Lincoln, NE)
were added to the membrane and allowed to incubate for five minutes. Standard
sensitivity was used at first then if the image was not detected clear, high sensitivity was
used.
Statistical Analysis
Data were analyzed using GraphPad and presented as mean±standard error of the
mean (SEM). Outliers above or below two standard deviations (SD) from the mean were
removed before data analysis. A two-way ANOVA was performed to determine main
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effects of Cr (diet) and DOX (drug) along with diet and drug interactions in cytochrome c
and cleaved caspase-9 protein expression. Tukey’s post hoc testing was performed if
there were significant main effects of interactions to identify where differences existed.
Significance was set at α=0.05.
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CHAPTER IV
RESULTS
The purpose of this study was to exam in the effects of the two different
treatments of Cr supplementation on cytochrome c and caspase-9 protein expressions in
SOL and EDL from rats administered DOX injections at two different time points. Prior
to sacrifice, five rats did not survive (two from 4% Cr-DOX-1, one from 4% Cr-SAL-3,
and two from 4% Cr-DOX-3).
Biochemical Analysis
The 1-SOL, 1-EDL, 3-SOL, and 3-EDL were analyzed to determine the effects of
two different Cr treatments (2% Cr for four weeks and the Cr loading consisting of 4% Cr
for one week followed by 2% Cr for three-week) and DOX administration at 1-day and 3days prior to sacrifice on the protein expressions of cyt c and casp-9. Protein expression
was expressed relative to the expression of mouse monoclonal antibody GAPDH as the
loading control. Cytochrome c expression is shown in Table 1 (1-SOL and 3-SOL) and
Table 2 (1-EDL and 3-EDL), and casp-9 expression is shown in Table 3 (1-SOL and 3SOL) and Table 4 (1-EDL and 3-EDL).
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Table 1
Cyt c Western Blot expressions
Muscle

CON-SAL

CON-DOX

2% Cr-SAL

2% Cr-DOX

4% Cr-SAL

4% Cr- DOX

1-SOL

0.31 ± 0.03

0.37 ± 0.06

0.34 ± 0.03

0.39 ± 0.03

0.49 ± 0.05

0.40 ± 0.03

3-SOL

0.30 ± 0.03

0.48 ± 0.11

0.49 ± 0.04

0.60 ± 0.09

0.34 ± 0.06

0.44 ± 0.10

Note. Cyt c= cytochrome c, 1-SOL= one-day soleus, 3-SOL = three-day soleus, CONSAL = control diet saline, n=10, n=8, CON-DOX = control diet doxorubicin, n=9, n=10,
2% Cr-SAL = 2% creatine diet saline, n=8, n=8, 2% Cr-DOX = 2% creatine diet
doxorubicin, n=8, n=10, 4% Cr-SAL = creatine loading saline, n=10, n=8, 4% Cr-DOX
= creatine loading doxorubicin, n=8, n=9. Values are means ± SEM.
Table 2
Cyt c Western Blot expressions
Muscle

CON-SAL

CON-DOX

2% Cr-SAL

2% Cr-DOX

4% Cr-SAL

4% Cr- DOX

1-EDL

0.24 ± 0.10

0.41 ± 0.15

0.41 ± 0.14

0.35 ± 0.11

0.27 ± 0.11

0.39 ± 0.15

3-EDL

0.56 ± 0.13

0.63 ± 0.14

0.69 ± 0.16

0.54 ± 0.13

0.60 ± 0.15

0.61 ± 0.05

Note. Cyt c= cytochrome c, 1-EDL= one-day extensor digitorum longus, 3-EDL = threeday extensor digitorum longus, CON-SAL = control diet saline, n=10, n=10, CON-DOX
= control diet doxorubicin, n=10, n=10, 2% Cr-SAL = 2% creatine diet saline, n=10,
n=10, 2% Cr-DOX = 2% creatine diet doxorubicin, n=10, n=9, 4% Cr-SAL = creatine
loading saline, n=10, n=10, 4% Cr-DOX = creatine loading doxorubicin, n=8, n=7.
Values are means ± SEM.
Table 3
Casp-9 Western Blot expressions
Muscle

CON-SAL

CON-DOX

2% Cr-SAL

2% Cr-DOX

4% Cr-SAL

4% Cr- DOX

1-SOL

0.69 ± 0.05

0.69 ± 0.06

0.66 ± 0.07

0.79 ± 0.09

0.91 ± 0.11

0.89 ±0.10

3-SOL

0.65 ± 0.15

0.82 ± 0.14

0.81 ± 0.10

0.98 ± 0.14

1.00 ± 0.16

1.03 ± 0.23

Note. Casp-9= caspase-9, 1-SOL= one-day soleus, 3-SOL = three-day soleus, CON-SAL
= control diet saline, n=9, n=10, CON-DOX = control diet doxorubicin, n=9, n=10, 2%
Cr-SAL = 2% creatine diet saline, n=8, n=9, 2% Cr-DOX = 2% creatine diet
doxorubicin, n=10, n=10, 4% Cr-SAL = creatine loading saline, n=10, n=9, 4% Cr-DOX
= creatine loading doxorubicin, n=10, n=9. Values are means ± SEM.
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Table 4
Casp-9 Western Blot expressions
Muscle

CON-SAL

CON-DOX

2% Cr-SAL

2% Cr-DOX

4% Cr-SAL

4% Cr- DOX

1-EDL

0.05 ± 0.01

0.06 ± 0.01

0.07 ± 0.02

0.09 ± 0.02

0.09 ± 0.02

0.06 ± 0.01

3-EDL

0.06 ± 0.01

0.07 ± 0.01

0.07 ± 0.02

0.06 ± 0.02

0.08 ± 0.02

0.10 ± 0.02

Note. Casp-9= caspase-9, 1-EDL= one-day extensor digitorum longus, 3-EDL = threeday extensor digitorum longus, CON-SAL = control diet saline, n=10, n=7, CON-DOX
= control diet doxorubicin, n=10, n=9, 2% Cr-SAL = 2% creatine diet saline, n=8, n=9,
2% Cr-DOX = 2% creatine diet doxorubicin, n=10, n=8, 4% Cr-SAL = creatine loading
saline, n=10, n=8, 4% Cr-DOX = creatine loading doxorubicin, n=6, n=6. Values are
means ± SEM.
Cytochrome c
The protein expression of cyt c was measured to see if there was an initiation of
apoptosis with the effects of Cr supplementation and DOX administration. In the 1-SOL,
no significant effects of the Cr supplementation (p=0.08) and the DOX injection (p=0.85)
were observed. The interaction between the Cr supplementation and the DOX injection
was not significant (p=0.17). The cyt c expression, however, in the CON-DOX increased
by 19.4% compared to the CON-SAL group. 2% Cr-DOX showed an increase of 14.7%
from the 2% Cr-SAL group while there was a 18.4% decrease of cyt c expression in the
4% Cr-DOX group compared to 4%-Cr SAL (Figure 2). There were no significant effects
of the Cr diet treatments (p=0.10) and the DOX administration (p=0.09) in the 3-SOL. No
significant interaction between the Cr diet treatments and the DOX administration was
observed (p=0.87). In the CON groups, DOX increased the expression of cyt c by 60%.
There was a 22.4% increase in 2% Cr-DOX compared to 2% Cr-SAL. DOX also
increased the protein expression by 29.4% in 4% Cr group (Figure 3).
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Figure 2. Cyt c expression in 1-SOL.
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 1-SOL= one-day soleus, SAL=
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine
loading; control diet saline, n=10, control diet doxorubicin, n=9, 2% creatine diet saline,
n=8, 2% creatine diet doxorubicin, n=8, creatine loading saline, n=10, creatine loading
doxorubicin, n=8. Values are mean ± SEM.
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Figure 3. Cyt c expression in 3-SOL.
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 3-SOL= three-day soleus,
SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%=
creatine loading; control diet saline, n=8, control diet doxorubicin, n=10, 2% creatine
diet saline, n=8, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=8,
creatine loading doxorubicin, n=9. Values are mean ± SEM.
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In the 1-EDL, the effects of the Cr diet treatments and the DOX administration
were not significant (p=0.89 and p=0.46, respectively). There was no significant
interaction with the Cr supplementation and the DOX injection (p=0.63). Doxorubicin
administration increased cyt c expression by 70.8% in the CON group. A 14.6% decrease
was observed in the 2% Cr-DOX compared to the 2% Cr-SAL group while the
expression of cyt c increased by 30.8% in the 4% Cr-DOX group compared to the 4% CrSAL group (Figure 4). In the 3-EDL, there was no significant effects of the Cr
supplementation observed (p=0.99). The DOX injection showed no significant effect
either (p=0.84). The interaction between the Cr diet treatments and the DOX injection
was not significant (p=0.71). Cytochrome c expression had a 12.5% increase in the CONDOX group compared to the CON-SAL group. The DOX administration decreased the
protein expression by 21.7% in the 2% Cr group. There was a 1.7% increased expression
of cyt c observed in the 4% Cr-DOX group compared to the 4% Cr-SAL group (Figure
5).
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Figure 4. Cyt c expression in 1-EDL.
Cyt c= cytochrome c (15 kDa), 3-EDL= one-day extensor digitorum longus, SAL=
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine
loading; control diet saline, n=10, control diet doxorubicin, n=10, 2% creatine diet
saline, n=10, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=10, creatine
loading doxorubicin, n=8. Values are mean ± SEM.
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Figure 5. Cyt c expression in 3-EDL.
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 3-EDL= three-day extensor
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2%
creatine diet, 4%= creatine loading; control diet saline, n=10, control diet doxorubicin,
n=10, 2% creatine diet saline, n=10, 2% creatine diet doxorubicin, n=9, creatine loading
saline, n=10, creatine loading doxorubicin, n=7. Values are mean ± SEM.
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Caspase-9
The casp-9 expression was examined to see the initiation of caspase cascademediated apoptosis. There were no significant effects of the Cr supplementation and the
DOX administration (p=0.63 and p=0.09, respectively). The interaction between the Cr
supplementation and the DOX administration was not significant (p=0.68). In the 1-SOL,
the expression of casp-9 of the CON group remained the same with the DOX injection.
The 2% Cr-DOX had a 19.7% increase compared to the 2% Cr-DOX group. The DOX
injection decreased the protein expression of casp-9 by 2.2% in 4% Cr-DOX group
compared to the 4% Cr-SAL (Figure 6). No significant effects of the Cr diet treatment
and the DOX injection were observed in the 3-SOL (p=0.21 and p=0.34, respectively).
No significant interaction was observed with the Cr diet treatment and the DOX
administration (p=0.88). The DOX administration in all three Cr diet groups (CON, 2%
Cr, and 4% Cr) increased the casp-9 expression by 26.2%, 21.0%, and 3%, respectively,
compared to the SAL group (Figure 7).
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Figure 6. Casp-9 expression in 1-SOL.
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 1-SOL= one-day soleus, SAL=
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine
loading; control diet saline, n=9, control diet doxorubicin, n=9, 2% creatine diet saline,
n=8, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=10, creatine loading
doxorubicin, n=10. Values are mean ± SEM.
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Figure 7. Casp-9 expression in 3-SOL.
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 3-SOL= three-day soleus, SAL=
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine
loading; control diet saline, n=10, control diet doxorubicin, n=10, 2% creatine diet
saline, n=9, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=9, creatine
loading doxorubicin, n=9. Values are mean ± SEM.
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In the 1-EDL, no significant effects were observed in the Cr diet treatments
(p=0.13) and the DOX administration (p=0.21). The interaction with the Cr
supplementation and the DOX injection was also not significant (p=0.27). The DOX
injection increased the protein expression of casp-9 in the CON and 2% Cr groups by
20.0% and 28.6%, respectively. However, the 4% Cr-DOX group had a 33.3% decrease
compared to the 4% Cr-SAL (Figure 8). In the 3-EDL, there were no significant effects in
the Cr supplementation (p=0.10) and the DOX administration(p=0.54). The interaction
between the Cr diet treatment and the DOX injection was not significant (p=0.51). A 16%
increase was measured in the CON-DOX group compared to the CON-SAL. The DOX
administration in the 2% Cr group decreased the casp-9 expression by 14.3% while the
4% Cr-DOX increased the expression by 25.0% compared to the 4% Cr-SAL (Figure 9).
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Figure 8. Casp-9 expression in 1-EDL.
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 1-EDL= one-day extensor
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2%
creatine diet, 4%= creatine loading; control diet saline, n=10, control diet doxorubicin,
n=10, 2% creatine diet saline, n=8, 2% creatine diet doxorubicin, n=10, creatine loading
saline, n=10, creatine loading doxorubicin, n=6. Values are mean ± SEM.
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Figure 9. Casp-9 expression in 3-EDL.
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 3-EDL= one-day extensor
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2%
creatine diet, 4%= creatine loading; control diet saline, n=7, control diet doxorubicin,
n=9, 2% creatine diet saline, n=9, 2% creatine diet doxorubicin, n=8, creatine loading
saline, n=8, creatine loading doxorubicin, n=6. Values are mean ± SEM.
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CHAPTER V
DISCUSSION
The main purpose of this study was to determine changes of the initiator apoptotic
enzyme expressions cyt c and casp-9 in type I and type II skeletal muscles treated with
two different Cr supplement treatments and two different time points of DOX
administrations. In addition, the interaction between the Cr supplementation and the
DOX administration was examined in this study. The results showed no significant
effects of the Cr supplementations and the DOX injections on cyt c and casp-9 in both the
SOL and EDL. No significant interaction was observed between the Cr diet treatment and
the DOX administration.
Even though the results did not indicate significant effects of Cr supplementation
and DOX injections, a potential trend toward Cr supplementation providing protection
with DOX administration in 1-EDL and 3-SOL were observed. The expression of cyt c of
the 3-SOL was attenuated in 4% Cr-SAL and 4% Cr-DOX by 30.6% and 26.7%,
respectively, compared to the 2% Cr-SAL and 2% Cr-DOX groups, respectively. Also,
the attenuated casp-9 expression was observed in the 1-EDL, treated with the Cr loading
diet treatment compared to the 2% Cr-DOX group. According to Hultman et al. (1996),
the Cr loading treatment increases total Cr concentration in skeletal muscle compared to a
steady amount of Cr supplemented. This finding may explain that the Cr loading
treatment group possibly had a higher total Cr concentration in the SOL and EDL
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compared to the 2% Cr treatment and thus may have attributed to prevent the initiation of
apoptosis in this study.
The gradual increase in the casp-9 expression, although not significant (p>0.05),
was observed in 1-SOL and 3-SOL with both the SAL and DOX injection. This finding
can be explained by the dimerization of cleaved casp-9. When procaspase-9 becomes
activated by Apaf-1, the cleaved casp-9 can lead to the activation of another procaspase-9
that was next to for its dimerization. The overexpression of cleaved casp-9 led to a 48%
increase in cleaved casp-9 expression in HeLa cells (Druskovic et al., 2006).
Additionally, the SOL muscles have a higher percentage of type I muscle fibers, also
known as slow-twitch fiber, compared to the EDL muscles (type IIb fiber/fast-twitch
fiber) in Sprague-Dawley rats (Armstrong & Phelps, 1984). The type 1 muscle fibers,
often utilized for aerobic activities, contain a higher oxidative capacity due to the higher
concentration of mitochondria and capillaries while the type IIb fibers has a low
mitochondrial density and less capillaries (Powers & Howley, 1995). Doxorubicin
treatment often triggers ROS production from mitochondria via DNA damage and lipid
peroxidation, which can lead to apoptosis (Min et al., 2015; Montaigne et al., 2011).
Since SOL muscles have a higher mitochondrial density than the EDL muscles, DOX
treatment could have been more effective with mitochondrial-ROS production and led to
the trend toward higher expression cleaved casp-9 in the SOL muscles.
Previous studies have proposed the prevention of apoptosis with the Cr
supplementation via increasing the activity of anti-apoptotic pathway (Caretti et al.,
2010), mitochondrial dysfunction signaling pathway (Ceddia & Sweeney, 2004) and
reducing ROS level in an oxidative environment (Lawler et al., 2002). Besides the
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defense mechanism of Cr, protein synthesis can be stimulated by Cr supplementation. In
Ingwall, Weiner, Morales, Davis, and Stockdale study (1974), 5 mM of Cr supplement in
cultured embryonic skeletal muscle with radioactive environment increased the synthesis
rate of two major contractile protein, actin and myosin heavy chains but did not affect
muscle degradation rate. Creatine supplement treatments did not significantly attenuate
the initiator apoptotic enzyme expressions in either type I or type II skeletal muscles in
the current study. With previous findings, Cr supplements may have affected protein
synthesis more rather than preventing the apoptosis in oxidative environment.
Multiple studies report that the combination of Cr supplementation and exercise
training increases body mass, anaerobic strength and power (M. Bemben et al., 2001),
improves in speed (Skare et al., 2001), and increases in myofibrillar protein and MHC
protein expressions (Willoughby & Rosene, 2001). Besides the improvement of exercise
performance, Cr also possesses the antioxidant capacity for quenching ROS, specifically
•

O−2 and OONO− according to previous research (Lawler et al., 2002). This antioxidant

capacity of Cr was observed in oxidative skeletal muscles that was induced by acute
exercise (Deminice & Jordao, 2012). However, Cr supplementation alone may not
improve skeletal muscle function or increase in contractile muscle protein expression.
According to Norman et al. (2006), a similar Cr supplement study without exercise was
done in colorectal cancer patients for eight weeks, and the results showed that grip
strength, knee extension strength, and hip flexion strength had no significant difference
between the Cr intervention group, consisting of 20 g/day for one-week followed by 5
g/day for 7 weeks, and the control group. The body cell mass (BCM) of the Cr
intervention group was also not significantly different from the control group. These
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results suggest that Cr supplementation alone cannot improve skeletal muscle functions
and increase protein synthesis. In this study, exercise was also not performed along with
the Cr supplement treatments. This may explain the increase in cyt c and casp-9
expressions in the skeletal muscles because the Cr supplementation alone cannot induce
its antioxidant effects without exercise.
Although the effects of Cr supplementation were not significant on the initiator
apoptotic enzymes with the DOX treatment in the current study, many researchers have
suggested Cr supplementation as a therapeutic agent in many disorders. According to
Kley, Tarnopolsky, and Vorgerd (2013), Cr supplementation significantly increased in
maximum voluntary contraction by 8.47% in patients suffering from muscle dystrophies.
Also, the significantly higher number of patients answered “feeling better” with the Cr
supplementation in the survey (p<0.05). Another study examined Cr’s effects in
Parkinson’s disease, neurodegenerative disorder that affects motor systems in skeletal
muscle. Patients with Cr supplementation combined with resistance training had
significantly increased muscular strength in biceps curl, chest press, and leg extension
(p<0.05). Additionally, muscle endurance for chest press and leg extension significantly
increased by 38% and 95%, respectively, in the Cr supplementation group with resistance
training (Hass, Collins, & Juncos, 2007). In Huntington disease involving mitochondrial
dysfunction and oxidative injuries, Cr supplementation reduced the oxidative stress level
in patients. Serum 8-hydroxy-2’-deoxyguanosine (8OH2’dG) was observed as a
biomarker of DNA oxidative injury and its level significantly reduced by 9.11 ± 13.93
pg/mL after 16 weeks of the Cr supplementation (5 g/day) (p<0.0042) (Hersch et al.,
2006). These promising therapeutic effects of Cr supplementation from previous studies
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should be investigated for future prevention and therapeutic mechanism for a variety of
disorder even though the current study did not find significant effects of Cr
supplementation in DOX treated skeletal muscles.
The limitation in this study was the uncertain and unequal amount of Cr
consumed by rats. The DOX group especially could have had less amount of the Cr
supplement compared to the SAL due to the loss of appetite, a common side effect of
DOX (Coates et al., 1983). Another limitation of this study was the unequal sample sizes
in each group due to the death of rats prior to tissue collections and removal of outliers
from the data set.
Further studies should investigate the effects of Cr supplementation and DOX
administration on the initiation of apoptosis in skeletal muscles. The rate of protein
synthesis and degradation should also be explored as previous studies discussed this
along with the apoptotic enzyme expressions. In addition, DOX-induced ROS production
should be measured to indicate the oxidative stress level in skeletal muscles. The
consumption of the Cr supplement should be measured to standardize the amount of Cr
stored in skeletal muscles as well. Exercise training should be also considered with Cr
supplementation to enhance the effects of Cr.
Conclusion
The present study examined the effects of Cr supplementation and DOX
administration on cyt c and casp-9 expressions in type I and type II skeletal muscles. In
addition, the interaction between the Cr supplementation and DOX administration was
examined in this study. There were no significant main effects of the Cr diet treatment or
DOX injection observed. The interaction between the Cr supplementation and the DOX
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injection was also not significant. However, a potential trend toward Cr providing
protection was observed in 1-EDL and 3-SOL by attenuating the increased expressions of
cyt c and casp-9 with the Cr loading treatment. Future research should be conducted with
the new interventions previously suggested to better understand the mechanisms of Cr
supplementation and the DOX administration in skeletal muscles.

60

References
Abramson, J. J., Buck, E., Salama, G., Casida, J. E., & Pessah, I. N. (1988) Mechanism
of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic
reticulum. Journal of Biological Chemistry, 263, 18750–18758.
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2008). Chapter
18 Apoptosis: Programmed Cell Death Eliminates Unwanted Cells. Garland
Science, 5, 1115.
Andrieu-Abaddie, N., Jaffrézou, J., Hatem, S., Laurent, G., Levade, T., & Mercadier, J.
(1999). L-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes:
role of inhibition of ceramide generation. The FASEB Journal, 13(12), 1501.
doi/10.1096/fasebj.13.12.1501.
Armstrong, R. B., & Phelps, R. O. (1984). Muscle fiber type composition of the rat
hindlimb. The American Journal of Anatomy, 171, 259-272.
Basu, A. K., Loechler, E. L., Leadon, S. A., & Essigmann, J. M. (1989). Genetic effects
of thymine glycol: site-specific mutagenesis and molecular modeling studies.
Proceedings of National Academy of Sciences of the United States of America, 86,
7677-7681.
Belizário, J. E., Lorite, M. J., & Tisdale, M. J. (2001). Cleavage of caspases-1, -3, -6, -8
and -9 substrates by proteases in skeletal muscles from mice undergoing cancer
cachexia. British Journal of Cancer, 84, 1135-1140.
Bemben, M. G., Bemben, D. A., Loftiss, D. D., & Knehans, A. W. (2001). Creatine
supplementation during resistance training in college football atheletes. Medicine
and Science in Sports and Exercise, 33(10), 1667-1673.
Berenblum, I. (1929). The modifying influence of dichloroethyl sulphide on the induction
of tumours in mice by tar. The Journal of Pathology and Bacteriology, 32, 424434.
Berlin, V., & Haseltine, W. A. (1981). Reduction of Adriamycin to a semiquinone-free
radical by NADPH cytochrome p-150 reductase produces DNA cleavage in a
reaction mediated by molecular oxygen. Journal of Biological Chemistry, 256,
4747-4756.

61
Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012). Oxidative
stress and antioxidant defense. World Allergy Organization Journal, 5(1), 9-19.
Bradford, M. (1976). A Rapid and Sensitive Method for the Quantitation of Microgram
Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical
Biochemistry, Analytical Biochemistry, 72(1-2), 248-254.
Brehdal, E., Pfannenstiel, K., Quinn, C., Hayward, R., & Hydock, D. (2016). Effects of
exercise on doxorubicin-induced skeletal muscle dysfunction. Medicine &
Science in Sports & Exercise, 48(8), 1468-1473.
doi:10.1249/MSS.0000000000000926.
Buttke, T. M., & Sandstrom, P. A. (1994). Oxidative stress as a mediator of apoptosis.
Immunology Today, 15(1), 7-10.
Caretti, A., Bianciardi, P., Sala, G., Terruzzi, C., Lucchina, F., & Samaja, M. (2010).
Supplementation of creatine and ribose prevents apoptosis in ischemic
cardiomyocytes. Cellular Physiology and Biochemistry, 26, 831-838.
Carpenter, A. J., & Porter, A. C. (2004). Construction, Characterization, and
complementation of a conditional-lethal DNA topoisomerase IIalpha mutant
human cell line. Molecular Biology of the Cell, 15, 5700-5711.
Casey, A., Constantin-Teodosiu, D., Howell, S., Hultman, E., & Greenhaff, P. L. (1996).
Creatine ingestion favorably affects performance and muscle metabolism during
maximal exercise in humans. American Journal of Physiology, 271, E31-E37.
Ceddia, R. B., & Sweeney, G. (2004). Creatine supplementation increases glucose
oxidation and AMPK phosphorylation and reduces lactate production in L6 rat
skeletal muscle cells. Journal of Physiology, 555(2), 409–421.
Chaires, J. B., Herrera, J. E., & Waring, M. J. (1990). Preferential binding of daunomycin
to 5′ATCG and 5′ATGC sequences revealed by footprinting titration experiments.
Biochemistry, 29, 6145–6153.
Chen, K. S., Gresh, N., & Pullman, B. (1986). A theoretical investigation on the sequence
selective binding of Adriamycin to double-strand polynucleotides. Nucleic Acids
Research, 14, 2251-2267.
Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002).
Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte
apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase
activity, and bcl-2:Bax ratio. Cancer Research, 62(16), 4592-4598.

62
Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., &
Tattersall, M. H. (1983). On the receiving end-patient perception of the sideeffects of cancer chemotherapy. European Journal of Cancer and Clinical
Oncology, 19(2), 203-208.
Coldwell, K. E., Cutts, S. M., Ognibene, T. J., Henderson, P. T., & Phillips, D. R. (2008).
Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at
clinically relevant Adriamycin concentrations. Nucleic Acids Research, 36, 100.
Cory, S., & Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death
switch. Nature Reviews Cancer, 2, 647-656.
Cotran, R. S., & Kumar, C. (1998). Robbins Pathologic Basis of Disease. W.B. Saunders
Company, 9th ed.
Demant, T. W., & Rhodes, F. C. (1999). Effects of creatine supplementation on the
exercise performance. Sports Medicine, 28(1), 46-60.
Deminice, R., & Jordao, A. A. (2012). Creatine supplementation reduces oxidative stress
biomarkers after acute exercise in rats. Amino Acids, 43(2), 709-15.
Devasagayam, T. P., Tilak, J. C., Boloor, K. K., Sane, K. S., Ghaskadbi, S. S., & Lele, R.
D. (2004). Free radicals and antioxidants in human health: current status and
future prospects. The Journal of the Association of Physicians of India, 52, 794804.
Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E., & Kumar, A. (2007).
TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal musclewasting cytokine. The FASEB Journal, 21, 1857–1869.
Doroshow, J. H. (1986). Role of hydrogen peroxide and hydroxyl radical formation in the
killing of Ehrlich tumor cells by anticancer quinones. Proceedings of the National
Academy of Sciences of the United States of America. 83(12), 4514-4518.
doi:10.1073/pnas.83.12.4514
Doroshow, J. H., Synold, T. W., Somlo, G., Akman, S. A., & Gajewski, E. (2001).
Oxidative DNA base modifications in peripheral blood mononuclear cells of
patients treated with high-dose infusional doxorubicin. Blood, 97, 2839-2845.
Druskovic, M., Suput, D., & Milisav, I. (2006). Overexpression of caspase-9 triggers its
activation and apoptosis in vitro. Croatian Medical Journal, 47(6), 832-840.
Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic
Pathology, 35(4), 495-516.

63
Ferraro, E., Fuoco, C., Strappazzon, F., & Cecconi, F. (2010). Apoptosome Structure and
Regulation. Springer. Dordrecht. 27-39. doi:10.1007/978-90-481-3415-1_2.
Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the
antitumor effects of the anthracycline antibiotics adriamycin and
daunorubicin. Biochemical Pharmacology, 57(7), 727-41.
Gilliam, L. A., Moylan, J. S., Patterson, E. W., Smith, J. D., Wilson, A. S., Rabbani, Z.,
& Reid, M. B. (2012). Doxorubicin acts via mitochondrial ROS to stimulate
catabolism in C2C12 mytobues. American Journal of Physiology-Cell Physiology,
302(1), 195-202. doi:10.1152/ajpcell.00217.2011.
Guimarães-Ferreira, L., Pinheiro, C. H., Gerlinger-Romero, F., Vitzel, K. F., Nachbar, R.
T., Curi, R., … Nunes, M. T. (2012). Short-term creatine supplementation
decreases reactive oxygen species content with no changes in expression and
activity of antioxidant enzymes in skeletal muscle. European Journal of Applied
Physiology, 112(11), 3905-11.
Han, D., Williams, E., & Cadenas, E. (2001). Mitochondrial respiratory chain-dependent
generation of superoxide anion and its release into the intermembrane space. The
Biochemical Journal, 353 (Pt 2), 411–416. doi:10.1042/0264-6021:350411.
Hardy, S., El-Assaad, W., Przybytkowski, E., Joly, E., Prentki, M., & Langelier, Y.
(2003). Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer
cells. A role for cardiolipin. The Journal of Biological Chemistry, 278(34),
31861-3170. doi:10.1074/jbc.m300190200.
Harris, R. C., Söderlund, K., & Hultman, E. (1992). Elevation of creatine in resting and
exercised muscle of normal subjects by creatine supplementation. Clinical
Science, 83, 367-374.
Hass, C. J., Collins, M. A., & Juncos, J. L. (2007). Resistance training with creatine
monohydrate improves upper-body strength in patients with Parkinson disease: a
randomized trial. Neurorehabilitation and Neural Repair, 21(2), 107-15.
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., … Rosas,
H. D. (2006). Creatine in Huntington disease is safe, tolerable, bioavailable in
brain and reduces serum 8OH2'dG. Neurology, 66(2), 250-2.
Hrelia, S., Fiorentini, D., Maraldi, T., Angeloni, C., Bordoni, A., Biagi, P. L., & Hakim,
G. (2002). Doxorubicin induces early lipid peroxidation associated with changes
in glucose transport in cultured cardiomyocyte. Biochimica et Biophisica Acta,
1567, 150-156. doi:10.1016/s0005-2736(02)00612-0.

64
Hultman, E., Söderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996).
Muscle creatine loading in men. Journal of Applied Physiology, 81(1), 232-237.
doi:10.1152/jappl.1996.81.1.232.
Hydock, D. S., Lien, C., Jensen, B. T., Schneider, C. M., & Hayward, R. (2011).
Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle
function in the rat. Anticancer Research, 31(6), 2023.
Ingwall, J. S., Weiner, C. D., Morales, M. F., Davis, E., & Stockdale, F. E. (1974).
Specificity of creatine in the control of muscle protein synthesis. Journal of Cell
Biology, 62(1), 145. doi:10.1083/jcb.62.1.145.
Jagoe, R. T., Lecker, S. H., Gomes, M., & Goldberg, A. L. (2002). Patterns of gene
expression in atrophying skeletal muscles: response to food deprivation. The
FASEB Journal, 16, 1697–1712.
Jena, N. R. (2012). DNA damage by reactive species: Mechanisms, mutation and
repair. Journal of Bioscience, 37(3), 503-17.
Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002). Apoptosis: A link between
cancer genetics and chemotherapy. Cell, 108(2), 153-164.
Karpinich, N. O., Tafani, M., Rothman, R. J., Russo, M. A., & Farber, J. L. (2002).
The Course of Etoposide-induced Apoptosis from Damage to DNA and p53
Activation to Mitochondrial Release of Cytochrome c. The Journal of Biological
Chemistry, 277, 16547-16552. doi: 10.1074/jbc.M110629200.
Kato, S., Burke, P. J., Fenick, D. J., Taatjes, D. J., & Bierbaum, V. M. (2000). Mass
spectrometric measurement of formaldehyde generated in breast cancer cells upon
treatment with anthracycline antitumor drugs. Chemical Research in Toxicology,
13, 509-516.
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013). Creatine for treating muscle
disorders. Cochrane Database of Systematic Reviews. (6), CD004760.
Kobayashi, T., Kuroda, S., Tada, M., Houkin, K., Iwasaki, Y., & Abe, H. (2003).
Calcium-induced mitochondrial swelling and cytochrome c release in the brain:
Its biochemical characteristics and implication in ischemic neuronal injury. Brain
Research, 960(1), 62-70. doi:10.1016/S0006-8993(02)03767-8
Kuida, K. (2000). Caspase-9. The International Journal of Biochemistry & Cell Biology,
32(2), 121-124. doi:10.1016.s1357-2725(99)00024-2.

65
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002). Direct
antioxidant properties of creatine. Biochemical and Biophysical Research
Communications, 290, 47–52.
L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Heide, R. V.
(2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte
death. American Journal of Physiology-Heart and Circulatory Physiology, 291,
H1273-H1280.
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., &
Wang, X. (1997). Cytochrome c and dATP-dependent formation of apaf1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91(4), 479-489.
doi:10.1016/S0092-8674(00)80434-1.
Li, P., Zhou, L., Zhao, T., Liu, X., Zhang, P., Liu, Y., … Li, Q. (2017). Caspase-9:
structure, mechanisms, and clinical application. Oncotarget, 8(14), 23996-24008.
Li, X., Fang, P., Mai, J., Choi, E. T., Wang, H., & Yang, X. F. (2013). Targeting
mitochondrial reactive oxygen species as novel therapy for inflammatory disease
and cancers. Journal of Hematology & Oncology, 6(19), 19.
doi:10.1016/j.freeradbiomed.2007.03.034
Lipshult, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders,
S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic
leukemia in childhood. New England Journal of Medicine, 324, 808-815.
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001). The TNF and TNF receptor
superfamilies: intergrating mammalian biology. Cell, 104(4), 487-501.
Lyu, Y. L., Kerrigan, J. E., Lin, C. P., Azarova, A. M., Tsai, Y. C., Ban, Y., & Liu, L. F.
(2007). Topoisomerase IIbeta mediated DNA double-strand breaks: implications
in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research,
15;67(18), 8839-8846.
MacLennan, D. H. (2000). Ca2+ signaling and muscle disease. European Journal of
Biochemistry, 267, 5291-5297.
Matsuura, K., Canfield, K., Feng, W., & Kurokawa, M. (2016). Metabolic regulation of
apoptosis in cancer. International Review of Cell and Molecular Biology, 327, 4387. doi:10.1016/bs.ircmb.2016.06.006.
Mattson, M. P., & Chan, S. L. (2003). Calcium orchestrates apoptosis. Nature Cell
Biology, 5(12), 1041–1043. doi:10.1038/ncb1203-1041.

66
Meyer, N., Kim, S. S., & Penn, L. Z. (2006). The Oscar-worthy role of Myc in apoptosis.
Seminars Cancer Biology. 16, 275-187.
Min, K., Kwon, O., Smuder, A. J., Wiggs, M. P., Sollanek, K. J., Christou, D. D., . . .
Powers, S. K. (2015). Increased mitochondrial emission of reactive oxygen
species and calpain activation are required for doxorubicin‐induced cardiac and
skeletal muscle myopathy. The Journal of Physiology, 593(8), 2017-2036.
doi:10.1113/jphysiol.2014.286518.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines:
molecular advances and pharmacologic develoments in antitumor activity and
cardiotoxicity. Pharmacological Reviews, 56(2), 185-229. doi:10.1124/pr.56.2.6
Momeni, H. R. (2011). Role of calpain in apoptosis. Cell Journal, 13(2), 65-72.
Momparler, R. L., Karon, M., Siegel, S. E., & Avila, F. (1976). Effect of adriamycin on
DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer
Reseaerch, 36(8), 2891-2895.
Montaigne, D., Marechal, X., Preau, S., Baccouch, R., Modine, T., Fayad, G., …
Neviere, R. (2011). Doxorubicin induces mitochondrial permeability transition
and contractile dysfunction in the human myocardium. Mitochondrion, 11, 22–26.
Muller, F. (2000). The nature and mechanism of superoxide production by the electron
transportchain: Its relevance to aging. Journal of the American Aging Association,
23(4), 227-53. doi:10.1007/s11357-000-0022-9.
Muller, F. L., Lustgarten, M. S., Jang, Y., Richardson, A., & Van Remmen, H. (2007).
Trends in oxidative aging theories. Free Radical Biology and Medicine, 43(4),
477-503. doi:10.1016/j.freeradbiomed.2007.03.034
Murphy, R. D., Stephenson, D., & Lamb, G. (2004). Effect of creatine on contractile
force and sensitivity in mechanically skinned single fibers from rat skeletal
muscle. American Journal of Physiology, 56(6), C1589.
Myers, C. (1998). The role of iron in doxorubicin-induced cardiomyopathy. Seminars in
Oncology, 25(4 suppl 10). 10-14.
Myers, C. E., McGuire, W. P., Liss, R. h., Ifrim, I., Grotzinger, K., & Young, R. C.
(1977). Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor
response. Science, 197(4299), 165-167. doi:10.1126/science.877547.
Mylonas, C., & Kouretas, D. (1999). Lipid peroxidation and tissue damage. In Vivo,
13(3), 295-309.

67
Nitiss, J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nature
Reviews Cancer, 338-350.
Norbury, C. J., & Hickson, I. D. (2001). Cellular responses to DNA damage. Annual
Review of Pharmacology and Toxicology. 41, 367-401.
Norman, K., Stübler, D., Baier, P., Schütz, T., Ocran, K., Holm, E., … Pirlich, M. (2006).
Effects of creatine supplementation on nutrition on status, muscle function and
quality of life in patients with colorectal cancer – a double blind randomized
controlled trial. Clinical Nutrition, 25(4), 596-605.
doi:10.1016/j.clnu.2006.01.014.
Orrenius, S., Gogvadze, V., & Zhivotovsky, B. (2015). Calcium and mitochondria in the
regulation of cell death. Biochemical and Biophysical Research Communications,
460(1), 72-81. doi:10.1016/j.bbrc
Pallepati, P., & Averill-Bates, D. A. (2011). Mild thermotolerance induced at 40 degrees
C protects HeLa cells against activation of death receptor-mediated apoptosis by
hydrogen peroxide. Free Radical Biology Medicine, 50, 667-679
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., … Neefjes, J.
(2013). Drug-induced histone eviction from open chromatin contributes to the
chemotherapeutic effects of doxorubicin. Nature Communications, 4, 1908.
Papac, R. J. (2001). Origins of cancer therapy. The Yale Journal of Biology and
Medicine, 74(6), 391-398.
Peter, M. E., & Krammer, P. H. (1998). Mechanisms of CD95 (APO-1/Fas)-mediated
apoptosis. Current Opinion in Immunology, 10, 545-551.
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010). DNA topoisomerases and their
poisoning by anticancer and antibacterial drugs. Cell Chemical Biology, 17, 421433.
Powers, S. K., & Howley, E. T. (1995). Exercise Physiology: Medicine & Science in
Sports & Exercise, 27(3), 466. doi:10.1249/00005768-199503000-00027
Rai, N. K., Tripathi, K., Sharma, D., & Shukla, V. K. (2005). Apoptosis: a basic
physiologic process in wound healing. The International Journal of Lower
Extremity Wounds, 4, 138-144.
Ray, P. D., Huang, B., & Tsuji, Y. (2012). Reactive oxygen species (ROS) homeostasis
and redox regulation in cellular signaling. United States Cell Signal, 24(5), 981990. doi:10.1016/j.cellsig.2012.01.008.

68
Reiter, R. J., Melchiorri, D., Sewerynek, E., Poeggeler, B., Barlow-Walden, L., Chuang,
J., . . . Acũna-Castroviejo, D. (1995). A review of the evidences supporting
melatonin’s role as an antioxidant. Journal of Pineal Research, 18(1), 1-11.
Rossouw, F., Kruger, P. E., & Rossouw, J. (2000). The effect of creatine: monohydrate
loading on maximal intermittent exercise sport-specific strength in well trained
power-lifters. Nurition Research, 20(4), 505-14.
Saelens, X., Festjens, N., Vande Walle, L., Van Gurp, M., Van Loo, G., & Vandenabeele,
P. (2004). Toxic proteins released from mitochondria in cell death. Ocogene, 23,
2861-2874.
Schuler, M., & Green, D. R. (2001). Mechanisms of p53-dependent apoptosis.
Biochemistry Society Transactions, 29, 684-688.
Schwartz, A. L. (2000). Daily fatigue patterns and effect of exercise in women with
breast cancer. Cancer Practice, 8(1), 16-24.
Shibutani, S., Takeshita, M., & Grollman, A. P. (1991). Insertion of specific bases during
DNA synthesis past the oxidation-damaged base-8oxodG. Nature, 349, 431-434.
Shidoji, Y., Hayashi, K., Komura, S., Ohishi, N., & Yagi, K. (1999). Loss of
molecular interaction between cytochrome c and cardiolipin due to lipid
peroxidation. Biochemical and Biophysical Research Communications, 264(2),
343-347.
Sies, H., Stahl, W., & Sundquist, A. R. (1992). Antioxidant functions of vitamins.
Vitamins E and C, beta-carotene, and other carotenoids. Annals of the New York
Academy of Sciences, 669, 7-20.
Skare, O. C., Skadberg, O., & Wisnes, A. R. (2001). Creatine supplementation improves
sprint performance in male sprinters. Scandanavian Journal of Medicine and
Science in Sports, 11(2), 96-102.
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. (2011). Execise protects against
doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. Journal
of Applied Physiology, 110(4), 935-942. doi:10.1152/japplphysio.00677.2010.
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., . . .
Kroemer, G. (1999). Molecular characterization of mitochondrial apoptosisinducing factor. Nature, 397, 441-446.
Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006).
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell
death. Cancer Research, 66, 4863-4871.

69
Taatjes, D. J., Gaudiano, G., Resing, K., & Koch, T. H. (1996). Alkylation of DNA by
the anthracycline, antitumor drugs Adriamycin and daunomycin. Journal of
Medicinal Chemistry, 39, 4135-4138.
Takemura, G., & Fujiwara, H. (2007). Doxorubicin-induced cardiomyopathy from the
cardiotoxic mechanisms to management. Progress in Cardiovascular Disease.
49(5), 330-52.
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., &
Altman, R. B. (2011). Doxorubicin pathways: pharmacodynamics and adverse
effects. Pharmacogenetics and Genomics, 21(7), 440-6.
Tiku, M. L., Narla, H., Jain, M., & Yalamanchili, P. (2007). Glucosamine prevents in
vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation
reactions and protein oxidation. Arthritis Research & Therapy. 9(4), R76.
doi:10.1186/ar2274.
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., & Telser, J. (2007). Free
radicals and antioxidants in normal physiological functions and human
disease. International Journal of Biochemistry & Cell Biology. 39(1), 44–84.
Van Norren, K., Van Helvoort, A., Argiles, J. M., Van Tuijl, S., Arts, K., Gorselink,
M., . . . Van der Beek, E. M. (2009). Direct effects of doxorubicin on skeletal
muscle contribute to fatigue. British Journal of Cancer, 100(2), 311-314.
doi:10.1038/sj.bjc.6604858
Walker, J. (1979). Creatine: biosynthesis, regulation, and function. Advances in
Enzymology, 50, 117-242.
Wang, I., Lin-Shiau, S., & Lin, J. (1999). Induction of apoptosis by apigenin and related
flavonoids through cytochrome c release and activation of caspase-9 and caspase3 in leukaemia HL-60 cells. European Journal of Cancer, 35(10), 1517-1525.
doi:10.1016/S0959-8049(99)00168-9
Wang, S., Konorev, E. A., Kotamraju, S., Joseph, J., Kalivendi, S., & Kalyanaraman, B.
(2004). Doxorubicin induces apoptosis in normal and tumor cells via distinctly
different mechanisms. Intermediacy of H2O2- and p53-dependent pathways.
Journal of Biological chemistry, 279, 25535-25543.
Willoughby, D. S., & Rosene, J. (2001). Effects of oral creatine and resistance training on
myosin heavy chain expression. Medicine and Science in Sports and
Exercise, 33(10), 1674-1681. doi:10.1097/00005768-200110000-00010

70
Wu, C., Li, T., Farth, L., Lin, L., Lin, T., Yu, Y., … Chan, N. (2011). Structural Basis of
Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide. Science,
333(6041), 459-462. doi:10.1126/science.1204117
Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014). Doxorubicin, DNA torsion,
and chromatin dynamics. Biochimica et. Biophysica Acta, 1845(1). 84-89.
doi:10.1016/j.bbcan.2013.12.002.
Yoshida, M., Shiojima, I., Ikeda, H., & Komuro, I. (2009). Chronic doxorubicin
cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis
pathway and attenuated by pitavastatin through the inhibition of Rac1 activity.
Japan Jurnal of Molecular and Cellular Cardiology, 47, 698-705.
Yquel, R. J., Arsac, L. M., Thiaudiere, E., Canioni, P., & Manier, G. (2002). Effect of
creatine supplementation on phosphocreatine resynthesis, inorganic ing phase, in
that highly trained individuals may not phosphate accumulation and pH during
intermittent maximal exercise. Journal of Sports Sciences, 20(5), 427-437.
Yuan, J., Murrell, G., Trickett, A., & Wang, M. (2003). Improvement of cytochrome c
release and caspase-3 activation in the oxidative stress-induced apoptosis in
human tendon fibroblasts. Biochimica et Biophsica Acta, 1641(1), 35-41.
doi:10.1016/S0167-4889(03)00047-8.
Zarkovic, N. (2003). 4-Hydroxynonenal as a bioactive marker of pathophysiological
processes. Molecular Aspects of Medicine, 24(4-5), 281-291. doi:10.1016/s00982997(03)00023-2.
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T.
(2012). Identification of the molecular basis of doxorubicin-induced
cardiotoxicity. Nature Medicine, 18, 1639-1642.
Zhivotovsky, B., Samali, A., Gahm, A., & Orrenius, S. (1999). Caspases: their
intracellular localization and translocation during apoptosis. Cell Death and
Differentiation, 6(7), 644-651. doi:10.1038/sj.cdd.4400536.

71

APPENDIX A
INSTITUTIONAL ANIMAL CARE AND USE
COMMITTEE APPROVAL

72

